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ABSTRACT
Traditional techniques of polymer synthesis produce macromolecules with
statistical distributions of chain length, composition, stereochemistry, and sequence.
Nature has evolved a complex system for polypeptide synthesis that gives essentially
complete control of chain length and monomer sequence.  Using the natural protein
biosynthesis machinery to produce protein polymers provides not only a unique
opportunity to study the effects of such molecular characteristics on material properties, but
also the possibility of readily incorporating bioactive domains into protein-based materials.
The objective of this thesis work was to expand upon the set of amino acids
available for incorporation into proteins in vivo and to explore applications of the novel
chemistries and physical properties provided by the new analogs.
Chapter 2 describes the incorporation of new unsaturated analogues of isoleucine,
the alkene 2-amino-3-methyl-4-pentenoic acid and the alkyne 2-amino-3-methyl-4-
pentynoic acid, by the wild type E. coli biosynthetic apparatus.  Incorporation was found to
be sensitive to side chain stereochemistry in the case of the alkene analog; the translational
activity of the pairs of enantiomers (SS, RR and SR, RS) were markedly different.  We
concluded that, although the SS-isomer is a good analogue, the SR-isomer is not
incorporated into proteins by this expression host.
Chapter 3 focuses on the incorporation of a fluorine-containing noncanonical
amino acid, 5,5,5-trifluoroisoleucine, into artificial extracellular matrix proteins.  The
fluorinated proteins displayed altered solubility phase behavior and were more resistant to
degradation by the physiologically relevant protease elastase, yet retained the ability to
adhere endothelial cells in a sequence specific manner.
v
Chapter 4 describes the incorporation of the photoreactive noncanonical analog
p-azidophenylalanine into artificial extracellular matrix proteins.  Films of the azide-
containing proteins were crosslinked upon short exposure to ultraviolet radiation.  Using
simple patterned masks, we demonstrated the ability to pattern protein films by only
exposing certain regions.  When protein patters were produced on a non-adhesive
background, endothelial cells selectively adhered to the protein regions to create stable cell
patterns.
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ABBREVIATIONS
2xYT two times yeast/tryptone medium
5TFI 5,5,5-trifluoroisoleucine
aaRS aminoacyl-tRNA synthetase (*)
aECM artificial extracellular matrix protein
ATP-PPi adenosine triphosphate-pyrophosphate
βME β-mercaptoethanol
BSA bovine serum albumin
CAI cell adhesion index
Cbz N-benzyloxycarbonyl
CD circular dichroism
Cy2 cyanine dye 2
DAPI 4′, 6 diamindine-2-phenyl indole
DMSO dimethylsulfoxide
dpi dots per inch
DPN dip-pen nanolithography
E elastic modulus
ECM extracellular matrix
EDTA ethylenediaminetetraacetic acid
E-Ile 2-amino-3-methyl-4-pentenoic acid
E. coli Escherichia coli
FTIR Fourier transform infrared spectroscopy
HLE human leukocyte elastase
1H-NMR proton nuclear magnetic resonance (spectroscopy)
HUVEC human umbilical vein endothelial cells
IleRS isoleucyl-tRNA synthetase
IPTG isopropyl-β-D-thiogalactopyranoside
L-allo-Ile (2S, 3R) 2-amino-3-methyl-4-pentanoic acid
xiii
LCST lower critical solution temperature
M9 or M9AA minimal medium
MALDI-MS matrix-assisted laser desorption ionization-mass spectrometry
mDHFR murine dihydrofolate  reductase
NEB New England Biolabs
OD optical density
PBS phosphate-buffered saline
PEG poly(ethylene  glycol)
PheRS phenylalanyl-tRNA synthetase
PMSF phenylmethylsulfonyl fluoride
pN3Phe para-azidophenylalanine
PPi sodium pyrophosphate
SDS-PAGE sodium dodecyl sulfate - polyacrylamide gel electrophoresis
Y-Ile 2-amino-3-methyl-4-pentynoic acid
Common abbreviations for the twenty canonical amino acids
amino acid 3-letter 1-letter amino acid 3-letter 1-letter
alanine Ala A leucine Leu L
arginine Arg R lysine Lys K
aspartic acid Asp D methionine Met M
asparagine Asn N phenylalanine Phe F
cysteine Cys C proline Pro P
glutamic acid Glu E serine Ser S
glutamine Gln Q threonine Thr T
glycine Gly G tryptophan Trp W
histidine His H tyrosine Tyr Y
isoleucine Ile I valine Val V
*The abbreviation for an aminoacyl-tRNA synthetase specific to an amino acid is formed
by placing the appropriate three-letter amino acid abbreviation before the letters RS.  For
example, the isoleucyl-tRNA synthetase is abbreviated IleRS.
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       C h a p t e r  I
C h a p t e r  I  C h a p t e r  I
INTRODUCTION
Traditional techniques of polymer synthesis produce macromolecules with
statistical distributions of chain length, composition, stereochemistry, and sequence.
Nature has evolved a complex system for polypeptide synthesis that gives essentially
complete control of chain length and monomer sequence.  Using the natural protein
biosynthesis machinery to produce protein polymers provides not only a unique
opportunity to study the effects of such molecular characteristics on material properties,
but also the possibility of readily incorporating bioactive domains into protein-based
materials.
Biomaterials produced through protein biosynthesis are limited, however, to the
chemical functionality contained within the canonical set of 20 amino acids (Figure I-1).
The incorporation of noncanonical amino acids makes possible the introduction of new
functionality into proteins, creating the potential for novel material properties or
interesting post-translational modifications.  This thesis describes a series of
investigations that i) expand the number of amino acids available for in vivo
incorporation into proteins and ii) use the new physical and chemical properties provided
by noncanonical amino acids to produce interesting materials.
The first step toward the goal of producing polypeptide polymers containing new
amino acid functionality must be an understanding of how proteins are synthesized in
nature.
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aliphatic
aromatic
polar
basic
acidic
Figure I-1.  The 20 canonical amino acids contain a variety of functional groups.
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I.1 Protein Biosynthesis
Synthesis by the natural biosynthetic machinery involves transcription of DNA
into mRNA and translation of mRNA codons into an amino acid sequence by tRNA
(Figure I-2).  Each tRNA contains a three-base anticodon that permits recognition of the
codon(s) for the appropriate amino acid and, at the opposite end of the molecule, an
adenine that serves as the attachment point for the amino acid.  Amino acids are charged
onto the tRNA by aminoacyl-tRNA synthetases (aaRSs); the aminoacyl-tRNAs are then
transported to the ribosome by elongation factor Tu (EF-Tu).  The ribosome, a multi-unit
protein/RNA complex, guides the association of aminoacyl-tRNAs with their cognate
mRNA codons, and a peptide bond is formed between the growing protein chain and the
DNA
CGA
mRNA
amino
acid
GCU
amino acid
GCU
tRNA
 ATP
 Mg2+
protein
translation:
ribosome
tRNA charging:
aminoacyl-tRNA synthetase
transcription:  RNA polymerase
Figure I-2.  During protein biosynthesis the genetic information encoded in DNA is
transcribed into mRNA.  The message is translated into an amino acid sequence in the
ribosome where mRNA codons are “read” by the appropriate tRNA molecule that has been
charged with its cognate amino acid by an aminoacyl-tRNA synthetase.
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amino acid charged to the tRNA.  The selectivity of this process for the
appropriate amino acid is responsible for translational fidelity and is an important
consideration in the attempt to incorporate noncanonical amino acids in vivo.
I.1.1 Fidelity of Protein Biosynthesis
There are a number of points during protein biosynthesis that provide an
opportunity to assure that the correct amino acid is incorporated into the protein chain in
response to a codon.  The aaRSs recognize both the amino acid and one or more of its
cognate tRNAs, EF-Tu binds the aminoacyl-tRNA to deliver it to the ribosome, and the
ribosome itself recognizes the aminoacyl-tRNA.
There is considerable evidence that the aaRSs are largely responsible for the
fidelity of protein synthesis.  The ribosome discriminates between D- and L-α-amino
acids [1-3] and rejects large aromatic analogues with certain geometries [4], but is
otherwise relatively insensitive to amino acid structure.  Indeed, in in vitro translation
systems in which the amino acid is first attached to tRNA by chemical misacylation to
bypass the aaRSs [5], the ribosome has been shown to accept and incorporate dozens of
noncanonical amino acids into growing protein chains.  Incorporated analogues include
α-amino acids with side chains that are much larger and/or very chemically distinct from
the canonical amino acids [6-8] as well as non-α-amino acids [9], including α-hydroxy
acids [1, 10] and N-methyl amino acids [11, 12].
In the case of EF-Tu, it is known that the strength of binding of aminoacyl-tRNAs
is optimized when the amino acid is attached to its cognate tRNA [13]. Yet, again, EF-Tu
is promiscuous enough to transport to the ribosome a large number of misacylated tRNAs
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produced both in vitro [14] and in vivo [15]. The majority of the burden of
choosing the correct amino acid from the available intracellular pool rests with the aaRSs.
Each aaRS recognizes both an amino acid and its cognate tRNA(s).  Although
each aaRS has evolved to recognize a particular amino acid, common structural and
functional domains have been identified (for review, see [16]).  The aaRSs first catalyze
the activation of the carboxyl group of the amino acid by reaction with adenosine
triphosphate (ATP) to produce an aminoacyl adenylate.  The activated ester of the
aminoacyl adenylate reacts with the terminal hydroxyl group of tRNA to produce
aminoacyl-tRNA.  In some cases, the aaRS also catalyzes hydrolysis of improperly
charged and/or activated amino acids.
Once the tRNA is aminoacylated by the aaRS, it is transported by EF-Tu to the
ribosome where synthesis of the polypeptide chain is completed.  Accurate decoding of
genetic information is accomplished by the protein-mediated matching of amino acids
with oligonucleotide sequence.
I.2 Protein Polymers
To the synthetic polymer chemist, an attractive feature of the protein biosynthesis
machinery is its ability to precisely control the sequence of the growing polymer chain.
In nature, such a fine degree of molecular control permits the production of proteins with
invariable sequence and the ability to fold into well-defined, functional three-dimensional
structures.  Using the tools nature has developed provides the chemist with a way to
design and produce protein-based polymers with controlled molecular architecture.
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Early work in the Tirrell laboratory demonstrated the ability to
introduce novel material properties through the precise control of polymer architecture
afforded by the biosynthetic machinery.  The rod-like polymer poly(γ-benzyl-L-
glutamate) (PBLG) has been studied for its ability to form liquid crystalline phases; when
produced with low polydispersity (~1.2) by standard synthetic techniques such as ring-
opening polymerization of α-glutamic acid-N-carboxyanhydride, PBLG forms nematic
liquid crystalline phases [17].  However, when PBLG is prepared through post-
translational modification of bacterially produced poly(L-glutamic acid), a more ordered
smectic phase is formed; mass spectroscopy of such samples show the chain population is
of one uniform length [17].
Genetically templated synthesis also provides a straightforward method to include
bioactive domains in the polymer structure.  For example, the Tirrell laboratory has
produced a family of proteins designed to mimic the natural extracellular matrix [18].
These modular constructs contain repeating blocks of protein sequence, one block
derived from the structural protein elastin to impart appropriate mechanical properties
and another block derived from known cell-adhesive sequences of the natural
extracellular matrix protein fibronectin.  Such proteins, when crosslinked by various
methods, possess moduli within the range of native elastin [19,20] and adhere human
umbilical vein endothelial cells (HUVEC) in a sequence-specific manner [21].  Studies
involving these artificial extracellular matrix proteins (aECMs) will be the focus of
Chapters 3 – 5 of this thesis.
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Although in vivo synthesis of protein polymers has been shown to be a
powerful technique, a clear limitation is the availability of only 20 monomers — the 20
canonical amino acids — with a limited range of functionality (Figure I-1).  Expanding
the number of monomers beyond these 20 would provide access to new chemical
reactivity not available in wild type proteins.
I.3 Strategies for the Incorporation of Noncanonical Amino Acids
The protein biosynthetic machinery makes mistakes; error frequencies for
misreading a codon and incorporating the incorrect canonical amino acid are ~10-4 [22].
It has also long been recognized that certain noncanonical amino acids, e.g.,
selenomethionine [23], can infiltrate the biosynthetic machinery and be incorporated into
proteins in place of a structurally similar amino acid.  Work in several laboratories has
exploited this promiscuity to incorporate amino acids with a variety of functional groups
not contained within the canonical set [24-32].
To further expand the set of functional groups available to protein engineers,
several groups have been developing techniques to incorporate noncanonical amino
acids, both in bacterial and mammalian cells as well as in cell-free in vitro translation
systems.  Figure I-3 schematically illustrates the major strategies being applied for the
incorporation of noncanonical amino acids into proteins in vitro and in vivo.
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Figure I-3.  Schematic representation of the various strategies for incorporating noncanonical
amino acids into proteins.  This figure appeared in [15].
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I.3.1 In vitro incorporation
In the late 1980s Chamberlin [33] and Schultz [34] introduced an in vitro strategy
for incorporation of noncanonical amino acids through nonsense suppression by
chemically misacylated tRNA.  Many groups have since used this technology for site-
specific incorporation to study protein structure and function.
The nonsense suppression strategy uses translational read-through by a
chemically misacylated suppressor tRNA to incorporate noncanonical amino acids site-
specifically in response to a nonsense codon, usually the amber stop codon (TAG).
Because of limitations in suppressor efficiencies, protein yields are generally low (1 – 10
µg/mL) [35], but the precise control of the placement of the noncanonical analogue
makes this a powerful tool for studies of protein structure and function.
For example, Pollitt and coworkers have employed site-specific incorporation in
vitro to cage an aspartic acid side chain of a protein (p21ras) as its o-nitrobenzyl ester,
allowing them to photochemically control its interaction with a protein partner (p120-
GAP) [36].  Koh and coworkers have investigated the role of specific backbone amide
linkages in T4 lysozyme through substitution with ester bonds by incorporation of α-
hydroxy acids [10].
Site-specific incorporation has also been accomplished using codons other than
stop codons.  Frameshift suppression of four-base codons has been used by Sisido and
coworkers to incorporate a fluorophore-quencher pair at selected positions in strepavidin
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[37], and use of unnatural nucleosides iso-C and iso-G enabled the Hecht
group to incorporate iodotyrosine in response to the “65th codon” [38].
I.3.2 In vivo incorporation
I.3.2.1 Residue-specific incorporation (codon reassignment)
By reassigning all of the codons for a particular amino acid to a close structural
analogue, the noncanonical analogue can be incorporated at multiple sites throughout the
protein.  Using this technique, one can significantly change the physical properties of a
protein [28, 39, 40] or provide for multiple reactive sites for chemical modification, such
as labeling [25, 41] or crosslinking (Chapter 4).
Often codon reassignment is accomplished simply by starving an auxotrophic
Escherichia coli (E. coli) strain for a canonical amino acid in medium supplemented with
a close structural analogue.  Tang and coworkers [40] employed this strategy to replace
up to 92% of the leucine resides in the leucine-zipper protein A1 with trifluoroisoleucine.
The fluorinated leucine zippers displayed a 13°C increase in melting temperature (Tm) as
well as increased resistance to chemical denaturation.  Kiick and coworkers [25] also
used this method to incorporate the noncanonical amino acid azidohomoalanine into a
target protein, murine dihydrofolate reductase (mDHFR), which they then
chemoselectively labeled through Staudinger ligation with a phosphine bearing an
antigenic peptide.
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Access to a wider range of noncanonical amino acids for residue-
specific incorporation is provided through alterations of the wild-type biosynthetic
machinery.  Overexpression of the appropriate synthetase can improve the incorporation
of poorly activated analogues [39,42].  A more general strategy involves mutating the
aaRS to alter its substrate specificity at either the synthetic [24,26,43] or hydrolytic
[44,45] active site.  For example, Doring and coworkers demonstrated replacement of
valine by the noncanonical amino acid aminobutyrate in a strain harboring valyl-tRNA
synthetase (ValRS) with multiple mutations in the editing site [45].
A previously characterized mutant E. coli phenylalanyl-tRNA synthetase (PheRS)
[24,46], with an enlarged active site resulting from the mutation of residue 294 from
alanine to glycine, accepts a wide variety of phenylalanine analogues not incorporated by
wild-type E. coli hosts, including the photoreactive amino acid para-azidophenylalanine
[26].  Photocrosslinking of artificial proteins through this noncanonical amino acid is
described in Chapter 4 of this thesis.
I.3.2.2 Site-specific incorporation
Several research groups have developed technologies to site-specifically
incorporate noncanonical amino acids in vivo.  Lester and coworkers first demonstrated
site-specific incorporation in vivo through injection of chemically misacylated tRNA into
Xenopus oocytes [14] and have more recently expanded this strategy to mammalian cells
[47].
Furter [48] developed a successful system for site-specific incorporation in E. coli
by importing a yeast suppressor tRNA and yeast aminoacyl-tRNA synthetase to generate
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a “21st pair.”  Because the native E. coli tRNAPhe/PheRS pair was incapable of
activating p-fluorophenylalanine, this noncanonical analogue was selectively
incorporated by the heterologous 21st pair in response to amber stop codons.
Schultz and coworkers have expanded and improved upon this strategy.  Through
directed evolution of aaRSs that show high specificity toward a noncanoncial amino acid
[49], they have created E. coli hosts with 21st pairs incorporating p-acetylphenylalanine
[50] and benzophenone [51], among others.  They have also generated an organism with
a novel 21st amino acid by inserting an aaRS evolved to incorporate p -
aminophenylalanine and the biosynthetic genes for the amino acid into an E. coli host
[52].  Use of orthogonal 21st pairs has recently been expanded to Saccharomyces.
cerevisiae [53] and Chinese hamster ovary cells [54].
I.3.2.3 Multiple site-specific incorporation
Kwon and coworkers have described a system that takes advantage of the
degeneracy of the genetic code to “reassign” the phenylalanine wobble codon UUU to the
noncanonical amino acid 2-napthylalanine [55].  This technique is complementary to
other missense strategies such as nonsense and frameshift suppression, but offers the
unique ability to efficiently incorporate a noncanonical amino acid at multiple pre-
selected sites, e.g., throughout a single protein domain.
Using the strategies described in Section I.3.2, to date the Tirrell laboratory has
successfully incorporated the set of amino acids shown in Figure I-4 into proteins in vivo.
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Figure I-4.  Noncanonical amino acids incorporated into proteins in vivo by the Tirrell laboratory.  Amino acids in black are accepted by
the wild type E. coli biosynthetic machinery; those in blue require overexpression of the wild type aaRS; those in red require an active site
mutant aaRS; and those in purple require an editing site mutant aaRS.
OHH2N
O
H2N
O
OH OH
O
H2N
OHH2N
O
OHH2N
O
CF3
OH
O
H2N
CF3
OHH2N
O
OHH2N
O
OH
O
H2N OH
O
H2N
CF3
OH
O
H2N
HN OH
O
HN
S
OH
O
HN OH
O
OH
O
H2N
N3
OH
O
H2N
H2N
O
OH
CF3
Proline Analogues
Leucine Analogues
Phenylalanine Analogues
Methionine Analogues
Isoleucine Analogues
S
OHH2N
O
N
OHH2N
O
OHH2N
O
OHH2N
O
Br
OHH2N
O
I
OHH2N
O
N3
OHH2N
O
OHH2N
O
CN
OHH2N
O
O
OHH2N
O
O
CF3
OHH2N
O
OH
O
H2N H2N
O
OH OH
O
H2N
OHH2N
O
OHH2N
O
I-14
I.4 Thesis Objective
The objective of this thesis work was to expand upon the set of amino acids
available for incorporation into proteins in vivo and to explore applications of the novel
chemistries and physical properties provided by the new analogues.
Chapter 2 describes the incorporation of new, unsaturated analogues of isoleucine,
the alkene 2-amino-3-methyl-4-pentenoic acid (E-Ile) and the alkyne 2-amino-3-methyl-
4-pentynoic acid (Y-Ile), by the wild type E. coli biosynthetic apparatus.  The IleRS was
found to be sensitive to sidechain stereochemistry in the case of the alkene analogue; the
translational activity of the pairs of enantiomers (SS, RR-E-Ile and SR, RS-E-Ile) are
markedly different.  We conclude that although SS-E-Ile is a good substrate for the IleRS,
SR-E-Ile is not incorporated into proteins by wild type E. coli translational machinery.  At
least one stereoisomer of the alkyne analogue of Ile is also translationally active, although
the level of stereochemical purity of the amino acid samples was not sufficient to
determine whether a similar stereochemical discrimination existed for Y-Ile.
Chapter 3 focuses on the incorporation of a fluorinated noncanonical amino acid,
5,5,5-trifluoroisoleucine (5TFI), into artificial extracellular matrix proteins.  The
fluorinated aECMs displayed altered phase behavior and were more resistant to
degradation by the physiologically relevant protease elastase, yet retained the ability to
adhere endothelial cells in a sequence specific manner.
Chapter 4 describes the incorporation of the photoreactive noncanonical analogue
p-azidophenylalanine (pN3Phe) into artificial extracellular matrix proteins using an E.
coli host expressing a mutant PheRS (A294G) in which the active site has been expanded
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to accommodate larger amino acids.  Films of the azide-containing aECMs
were crosslinked upon short (~30 s) exposure to ultraviolet radiation at 365 nm.  Using
simple patterned masks, we demonstrated the ability to pattern protein films by only
exposing certain regions.  When protein patterns are produced on a non-adhesive
background, endothelial cells selectively adhere to the protein regions to create stable cell
patterns.
Chapter 5 describes progress toward the cloning of a new aECM construct
containing a very robust cell-adhesive domain as well as regular phenylalanine sites for
incorporation of pN3Phe.
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C h a p t e r  I I
C h a p t e r  I I  C h a p t e r  I I
STEREOSELECTIVE INCORPORATION OF UNSATURATED ISOLEUCINE
ANALOGUES INTO PROTEINS IN VIVO*
II.1 Abstract
The unsaturated amino acids 2-amino-3-methyl-4-pentenoic acid (E-Ile) and 2-
amino-3-methyl-4-pentynoic acid (Y-Ile) were prepared, and E-Ile was successfully
separated into its SS, RR and SR, RS diastereomeric pairs.  The translational activities of
the SS-E-Ile, SR-E-Ile, and Y-Ile analogues were assessed using an Escherichia coli (E.
coli) strain auxotrophic for isoleucine (Ile).  SS-E-Ile was incorporated into the test
protein murine dihydrofolate reductase (mDHFR) in place of isoleucine at a rate of
substitution of up to 72%, while SR-E-Ile showed no conclusive evidence of translational
activity.  At least one stereoisomer of Y-Ile also supported protein production, but the
stereochemical purity of the amino acid samples was not sufficient to investigate
stereochemical discrimination.   In vitro ATP-PPi exchange assays indicate that SS-E-Ile
is activated by the isoleucyl-tRNA synthetase (IleRS) at a rate comparable to isoleucine;
SR-E-Ile is activated approximately 100 times more slowly.
*Sections of this chapter are excerpted from a manuscript accepted to ChemBioChem by
Marissa L. Mock, Thierry Michon, Jan C. M. van Hest, and David Tirrell, 2005.
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II.2 Introduction
Genetic engineering provides a tool with which one can prepare complex
macromolecules possessing both precisely controlled architectures and specific catalytic
or biological activity.   Recent work has shown the advantages of using the biosynthetic
machinery to produce new materials (for a review see reference [1]).  The use of
monomers other than the twenty canonical amino acids enables the introduction of new
functionality into proteins, creating the potential for novel physical and chemical
properties.  Analogues of many of the canonical amino acids have been incorporated into
proteins in E. coli using the wild-type biosynthetic machinery, e.g. [2, 3], while
modifications of that machinery have permitted the incorporation of a still broader set of
non-canonical amino acids [4-14].  Increasing the number of amino acid monomers that
can be incorporated into proteins, and thereby the range of physical properties and
chemistries available, requires detailed understanding of the biosynthetic apparatus.
Protein synthesis involves transcription of the information contained in DNA into
mRNA and translation of the mRNA into polypeptide chains.  The aminoacyl-tRNA
synthetases (aaRSs) are essential to the fidelity of this process.  Each aaRS selectively
catalyzes the activation of the carboxylate group of the appropriate amino acid by
reaction with adenosine triphosphate (ATP) to produce the aminoacyl adenylate, which
reacts with terminal hydroxyl group of a cognate tRNA to produce aminoacyl-tRNA.
The selectivity of the aaRSs is an important consideration in any attempt to incorporate
nonnatural amino acids into proteins in vivo.  Modifications of the aaRSs, through
enlarging the active site [14-16] or decreasing editing activity [13, 17], have been shown
to permit incorporation of analogues that are not usually incorporated into proteins.  The
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rational modification of aaRSs to allow use of a wider range of nonnatural
amino acids requires an understanding of the mechanism(s) of selectivity of each
individual aaRS.
The isoleucyl-tRNA synthetase (IleRS) has been well studied, in part because it
must perform a significant feat of selective recognition as it discriminates its cognate
amino acid isoleucine (Ile) from the natural amino acid valine (Val), which differs in
chemical structure by only one methylene group.  Pauling calculated that the additional
binding energy contributed by the extra methylene group should at most result in a
discrimination of 1/20 [18], while the erroneous substitution of Val for Ile actually occurs
at a rate of about 1 in 3000 [19].  In fact, IleRS does misactivate Val (approximately 140
times more slowly than Ile [20, 21]) and later hydrolyzes the misactivated amino acid in
an editing site located ~34 Å from the synthetic site of the enzyme [22-24].  Isoleucine
contains two chiral centers, one at the alpha carbon and another at the beta carbon.  The
stereoisomer of 2-amino-3-methyl-heptanoic acid incorporated into proteins is (2S, 3S),
designated Ile.  L-allo-Ile (2S, 3R) has the correct configuration at the α-carbon, but the
opposite configuration at the β-position.  It is not incorporated into proteins, although
there is evidence that it is bound and activated by IleRS [19, 25-27].
To expand further the chemistries available for the modification of proteins, we
prepared the unsaturated Ile analogues (2S, 3S and 2R, 3R)-2-amino-3-methyl-4-pentenoic
acid (SS, RR-E-Ile), (2S, 3R and 2R, 3S)-2-amino-3-methyl-4-pentenoic acid (SR, RS-E-Ile),
and 2-amino-3-methyl-4-pentynoic acid (as a mixture of the S S, R R , SR, and R S
stereoisomers) (Figure II-1), which have been shown previously to inhibit growth of E.
coli [28].  We are especially interested in unsaturated amino acid analogues because of
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the versatile chemistry of alkenes and alkynes.  For example, supramolecular structures
made up of weakly hydrogen-bonded cyclic peptides can be stabilized through inter-
peptide crosslinking [29] utilizing ruthenium-catalyzed ring-closing metathesis of
pendant alkene moieties [30, 31] and Cu(I)-catalyzed azide-alkyne cycloaddition has
been used to modify E. coli cells [32].  The stereoisomer pairs were evaluated with
respect to incorporation into a test protein, murine dihydrofolate reductase (mDHFR), in
an E. coli strain rendered auxotrophic for Ile.  The kinetics of activation of SS and SR-E-
Ile by the IleRS were also determined in vitro through ATP/PPi exchange.
II.3 Methods
II.3.1 Synthesis of Analogues
II.3.1.1 General procedures
Glassware was dried at 150 °C and cooled under argon prior to use.
Tetrahydrofuran (THF) was freshly distilled from sodium/benzophenone.  Other reagents
were used as purchased.  Cis- and trans-crotyl alcohol were purchased from
Chemsampco, Trenton, NJ.  1H-NMR spectra were recorded on a Varian Mercury 300
MHz spectrophotometer.  Column chromatography was performed on silica gel (300
COOHH2N COOHH2NCOOHH2N
SS-E-Ile SR-E-IleSS-Ile
COOHH2N COOHH2N
SS-Y-Ile SR-Y-Ile
Figure II-1.  Unsaturated isoleucine analogues SS-E-Ile and S R-E-Ile differ in the
stereochemistry at the β-carbon.  The stereoisomer of isoleucine incorporated into proteins (Ile)
is 2S, 3S.
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Mesh, Baker) or alumina (80-200 Mesh, EM Science). Silica (60F254 EM
Science) was used for thin layer chromatography.
II.3.1.2 SS- and SR-2-amino-3-methyl-4-pentenoic acid (E-Ile)
SS- and SR-E-Ile were prepared according to Figure II-2; the stereochemistry at
the β-carbon of the final product was controlled by choosing either cis- or trans-crotyl
alcohol as the starting material (Figure II-3).  N-benzyloxycarbonyl (Cbz)-protected
glycine crotyl esters were prepared according to Hassner and Alexian [33], with slight
modification.  Cbz-glycine (17.44, 83.4 mmol) was dissolved in 100 mL THF under N2.
Either cis- or trans-crotyl alcohol (6.00 g, 83.2 mmol) was added, followed by 17.15 g
(83 mmol) dicyclohexyl carbodiimide and 50 mg (6.1 mmol) dimethylaminopyridine.
An exotherm was observed, and a precipitate immediately formed.  The mixture was
allowed to stir at room temperature for 2 days before being filtered through Celite.  The
or + O
O
N
H O
OH DCC, DMAP O
O
N
H O
O
LDA,
ZnCl2
O
O
N
H O
OH
trimethylsilyl iodide
H2N
O
OH
HO
HO
Figure II-2.  Synthesis scheme for SS- and SR-E-Ile.  The amine-protected crotyl esters
undergo Claisen rearrangement; subsequent deprotection gives stereochemically enriched
product.
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solvent was evaporated, and the crude product was purified by flash
chromatography (CH2Cl2).  A viscous colorless oil was obtained by evaporation of the
eluent (yield trans-isomer: 65 %, cis-isomer: 32 %).  1H-NMR (CDCl3): δ 1.73 (d, 3H, J
= 6.9, CH3), 3.98 (d, 2H, J = 6.4, CH2-CO), 4.57 (d, 2H, J = 6.7, O-CH2), 5.17 (s, 2H,
Ph-CH2), 5.56 (m, 1H, JE  = 17.4, JZ = 10.2, C=CH-CH3), 5.81 (m, 1H, JE  = 17.4, JZ =
10.2, O-CH2-CH=C), 7.35 (s, 5H, Ph).
N-benzyloxycarbonyl (Cbz)-protected glycine crotyl esters were rearranged
following Kazmaier [34] to N-benzyloxycarbonyl-2-amino-3-methyl-4-pentenoic acid.
Diisopropyl amine (6.9 mL, 45.8 mmol) was dissolved in 40 mL dry THF under argon.
Zn
O NZ
O
ZHN
O
OH
cis S,S
ZHN
O
O
chair-like transition state
Zn
O NZ
O
ZHN
O
OH
S,R
ZHN
O
O
trans chair-like transition state
Figure II-3.  Stereoselectivity in the preparation of E-Ile is a result of a preference for the
chair-like transition state during the Claisen rearrangement, which determines the
stereochemistry at the β-carbon in the product.  The trans-crotyl alcohol yields SR (and RS)-
E-Ile, while the cis-crotyl alcohol gives SS (and RR)-E-Ile.
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The stirred solution was cooled to –20 °C and 26 mL (41.6 mmol) 1.6 M n-
butyl lithium in n-hexane was added.  After 20 minutes, the solution was cooled to –78
°C, and 5.4 g (20.5 mmol) Cbz-protected glycine crotyl ester (either cis or trans) in 20
mL THF and 25 mL of a 0.5 M ZnCl2 solution in THF were added simultaneously over a
30 min period.  The solution remained homogeneous.  After an additional 30 min at –78
°C the solution was allowed to warm to room temperature.  The rearrangement was
monitored by thin layer chromatography (3: 7 ethyl acetate:dichloromethane).  After 5
hours, 30 % (trans) to 50 % (cis) of the starting ester was still present in the reaction
medium.  Additional incubation time did not improve the yield of the rearrangement.
The reaction was terminated by addition of 10 mL 1 M HCl.  The ether phase was
extracted with two 75 mL volumes of 1 M NaOH.  The aqueous phase was neutralized
with concentrated HCl to precipitate the acid product, which was extracted with diethyl
ether (150 mL).  The ether layer was dried over MgSO4, and the solvent was evaporated
to give a yellow oil.  The acids were purified by flash chromatography (99:1 ethyl
acetate:acetic acid).
Either SS, RR or RS, SR Cbz-protected 2-amino-3-methyl-4-pentenoic acid (0.8 g, 3
mmol) was dissolved in 10 mL dry CHCl3 under nitrogen atmosphere.  Trimethylsilyl
iodide (1.2 mL, 8.8 mmol) was added.  After 20 min stirring at room temperature, the
reaction was quenched by addition of 1 mL methanol.  The solvent was evaporated, the
crude product was dissolved in 10 mL 30 % v/v acetic acid, and the solution was washed
twice with 15 mL diethyl ether.  The aqueous layer was evaporated, yielding a yellow oil.
The SR, RS mixture of isomers crystallized upon cooling.  Recrystallization from 4:1
isopropanol:water gave 0.18 g (yield 45 %) of pure amino acid (d.e.=94%).  1H-NMR
II-8
(D2O) δ:  1.08 (d, 3H, J=7.0, CH-CH3), 2.8-2.9 (m, 1H, J1=4.1, J2=7.0, CH-
CH3,), 3.74 (d, 1H, J=4.1, NH2-CH-COOH), 5.20-5.27 (m, 2H, J1=5.9, J2=11.2,
CH=CH2), 5.76-5.88 (m, 1H, J1=6.2, J2=11.6, CH=CH2).
The crude SS, RR-isomer did not crystallize.  It was dissolved in 6 N HCl; the
hydrochloride was isolated by evaporation and dissolved in methanol.  The amino acid
was precipitated by slow addition of propylene oxide.  The precipitate was crystallized
from 4:1 isopropanol:water, yielding 0.116 g (29%) of pure SS, RR-E-Ile (d.e.=78%).  1H-
NMR (D2O) δ:  1.12 (d, 3H, J=7.0, CH-CH3), 2.75-2.85 (m, 1H, J1=6.9, J2=5.8, CH-
CH3), 3.57 (d, 1H, J=5.7, NH2-CH-COOH), 5.20-5.27 (m, 2H, J1=5.1, J2=11.1,
CH=CH2), 5.76-5.88 (m, 1H, J1=7.3, J2=10.1, CH=CH2).
The reaction products were recrystallized 5 times from 5:1 isopropanol:water to
give SS, RR-E-Ile (d.e. = 95%) and SR, RS-E-Ile (d.e. = 98%).
II.3.1.3 2-amino-3-methyl-4-pentynoic acid (Y-Ile)
The synthesis scheme for Y-Ile appears in Figure II-4.  Diphenylmethylene
glycine ethyl ester was prepared according to O'Donnell and Polt [35]. The 1H NMR
spectrum was in accord with Aidene and coworkers [36].
To prepare 3-bromobutyne, 6.82 g (62 mol) PBr3 containing 0.1 mg hydroquinone
and a solution of 10 g (0.14 mol) 3-butyn-2-ol in 1 mL dry pyridine were added dropwise
simultaneously over a 4-hour period to a 50 mL round bottom flask cooled to -15 °C,
maintained under argon, and equipped with a stirrer, an addition funnel, and a gas inlet.
After an additional 30 min of reaction, 20 mL of cold water were cautiously added to stop
the reaction.  The mixture was extracted with ether (3 x 20 mL).  The combined ether
layers were washed consecutively with water (3 x 20 mL), saturated sodium bicarbonate
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(3 x 25 mL), and saturated sodium chloride (2 x 50 mL).  The ether extract was dried
with MgSO4 and filtered.  The dry ether phase was immediately distilled, affording 8.1 g
(45%) of 3-bromobutyne.  1H-NMR (CDCl3): δ 1.90 (d, 3H, J = 7.1, CH3-CHBr), 2.63 (d,
1H, CHBr-CCH), 4.55 (m, 1H, J = 7.1, CH3-CHBr) ppm.
A solution of 1.16 mL (8.22 mmol ) diisopropylamine in 15 mL dry
tetrahydrofuran (THF) was cooled to –20 °C under an argon atmosphere.  A 1.6 M
solution of n-butyl lithium in n-hexane (5.13 mL, 8.22 mmol) was added by syringe, and
the mixture was stirred for 10 min. The lithium diisopropylamide solution was then
cooled to –70 °C, and a solution of 2 g (7.5 mmol) diphenylmethylene glycine ethyl ester
in 3 mL THF was slowly added.  After 30 min stirring, 1.0 g (7.5 mmol) 3-bromobutyne
was added over a 15 min period.  The reaction mixture was allowed to warm to room
NH H2N
O
O N
BrOH PBr3
pyridine
CH2Cl2
LDA
reflux
propylene
oxide
precipitation
O
O
N
O
O
H2N
O
O
H2N
O
OH 1 M HCl
6 M HCl
Figure II-4.  Y-Ile was prepared from diphenylmethylene glycine ethyl ester, which was alkylated
with 3-bromobutyne.  The alkylated product was deprotected to yield a mixture of stereoisomers
of Y-Ile.
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temperature and stirred for an additional 3 hours. The solvent was removed
by evaporation and the product purified by column chromatography (1:1 CH2Cl2:hexane).
The purified product was dissolved in 15 mL diethyl ether, and 15 mL of 1 M HCl was
added.  The mixture was stirred vigorously for 3 hours at room temperature.  The two
phases were separated, and the aqueous phase was washed twice with 10 mL diethyl
ether.  The aqueous layer was concentrated, and the residue was redissolved in 15 mL of
6 M HCl and heated to reflux for 6 hours.  The water was removed, and the residue was
taken up in 10 mL methanol and 5 mL propylene oxide and stirred for 12 hours at room
temperature.  The precipitate that formed was filtered and dried, yielding 0.25 g (27 %) of
Y-Ile.  The 1H-NMR spectrum was in agreement with that reported previously [36].
Statistical mixtures of all 4 stereiosmers were obtained; the product was recrystallized
four times from 5:1 isopropanol:water to give SS, RR-Y-Ile (d.e. = 81%) and SR, RS-Y-Ile
(d.e. = 60%).
II.3.2 Purification of IleRS
E. coli strain MV1184 transformed with the multicopy plasmid pkS21[37]
encoding the IleRS was kindly provided by Valerie de Crécy-Lagard and Paul Schimmel
at the Scripps Research Institute.  IleRS was expressed in 1 L (2xYT) cultures, and the
collected protein was purified by ammonium sulfate fractionation, cold water dialysis,
and anion exchange chromatography following an established protocol [38].  The
concentration of IleRS stock was determined by the Bradford method to be 0.13 mM.
II.3.3 ATP/PPi Exchange
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ATP-PPi exchange assays were performed as previously described
[39] in 150 mL of reaction buffer (pH 7.6, 20 mM imidazole, 0.1 mM EDTA, 10 mM β-
mercaptoethanol, 7 mM MgCl2, 2 mM ATP, 0.1 mg/ml BSA, and 2 mM PPi [
32P sodium
pyrophosphate with a specific activity of 0.1 mCi/ml]) with 75 nM IleRS and
concentrations of analogues from 10 mM to 1 mM.  Aliquots of 15-20 mL of each
reaction were removed at various time points and quenched in 0.5 ml of a solution of 200
mM PPi, 7 % v/v HClO4, and 3% w/v activated charcoal.  The charcoal was washed twice
with 0.5 ml of a solution of 10 mM PPi with 0.5% v/v HClO4 and resuspended in 0.5 ml
of this solution. Each charcoal suspension was transferred to a 20-mL scintiallation vial,
and 10 mL Safety-Solve liquid scintillation cocktail (Research Products Institute, Inc.)
was added before counting on a Beckman Coulter liquid scintillation counter.
II.3.4 Protein expression
To test for analogue incorporation, a 50 mL culture of M9AA medium
supplemented with ampicillin (200 mg/L), chloramphenicol (35 mg/L), 1 mM MgCl2, 0.1
mM CaCl2, 0.2 % glucose, and 1 mg/L thiamine was inoculated with a single colony of
the isoleucine auxotrophic expression system AI-IQ[PQE15] [40].  After overnight
growth at 37 °C, a 5 µL aliquot of culture was used to inoculate 50 mL of supplemented
M9AA medium (for small-scale expressions) or a 1 mL aliquot was used to inoculate 1 L
of medium (for large-scale expressions).  When the culture reached an OD600 of 0.9-1.0,
the cells were sedimented (5000g, 10 min, 4°C), washed twice with 0.9 % NaCl, and
resuspended in 50 mL fresh supplemented M9 medium containing 19 natural amino acids
(20 mg/L) but lacking isoleucine.  For tests of incorporation, the cultures were divided
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into aliquots, to which were added water (negative control), L-isoleucine
(positive control), L-valine, S S-E-Ile, SR-E-Ile, SS-Y-Ile, or S R-Y-Ile.  Tests of
incorporation using once-recrystallized SS-E-Ile (d.e. = 68 %) were performed in 10 mL
cultures; the concentrations of L-amino acid in the medium were 25, 50, and 125 mg/L.
Studies of SS-E-Ile (d.e. = 95 %) and SR-E-Ile (d.e. = 98 %) were performed at 130 mg/L
of the L-amino acid in 5 mL cultures, while studies of SS-Y-Ile (d.e. = 81%) and SR-Y-Ile
(d.e. = 60%) were performed at 100 mg/L in 5 mL cultures.  For large-scale expressions
of protein samples for 1H-NMR studies, the L-amino acid concentrations were 25 mg/L
and 125 mg/L SS-E-Ile (d.e. = 76%) and 70 mg/L SR-E-Ile (d.e. = 91%).  After 10 min of
growth, mDHFR expression was induced by addition of 1 mM IPTG.  After 4 h growth at
37 °C, the cells were sedimented (5000g, 10 min, 4°C), resuspended in 4 M urea, and
frozen at –20 °C overnight.  The cells were thawed, sonicated, and incubated for 30 min
at 37 °C with 10 mg/mL DNase, 10 mg/mL RNase, and 10 mM MgCl2 prior to
purification.  Protein expression was monitored by SDS-PAGE and Western blotting with
antibodies recognizing the histidine tag of mDHFR (Qiagen, Inc., Santa Clarita, CA,
USA) [41].
II.3.5 Mass spectrometry
Expressed mDHFR was purified from cell lysates by Ni affinity chromatography
using a Ni-NTA Spin Kit (Qiagen).  Purified mDHFR was incubated with trypsin in 50
mM ammonium bicarbonate buffer overnight at room temperature.  The proteolysis
product was purified by C18 ZipTip (Millipore), deposited in a matrix of α-cyano-4-
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hydroxycinnamic acid, and analyzed by MALDI-TOF mass spectrometry on
an Applied Biosystems Voyager DE Pro instrument.
II.3.6 1H-NMR spectroscopy
For 1H-NMR, samples of purified protein were dissolved in 0.1% DCl in D2O.
Samples of SS-E-Ile (6 mg/L) were prepared in standard tubes (700 µL volume), while
SR-E-Ile samples (4 mg/mL) were prepared in low volumes (300 µL) in solvent-matched
tubes (Shigemi, Inc.).  Spectra were collected on a Varian Inova NMR spectrometer with
proton acquisition at 599.69 MHz and with water suppression by presaturation.
II.4 Results
II.4.1 Synthesis of unsaturated amino acids
Kazmaier has shown that N-benzyloxycarbonylglycine trans-crotyl ester
undergoes a [3,3]-sigmatropic rearrangement [34] to yield Cbz-protected 2-amino-3-
methyl-4-pentenoic acid (E-Ile).  The reaction is stereoselective, giving mainly the SR, RS
pair of stereoisomers (95%).  Because it was of interest to compare the in vivo
incorporation of the two diastereomers SS-E-Ile and SR-E-Ile, we applied the Kazmaier
method also to Cbz-glycine cis-crotyl ester to obtain SS, RR-E-Ile (hereafter referred to as
SS-E-Ile).  The efficiency of rearrangement was lower than for the trans-ester, and the
work-up requires an additional step because of a lower tendency of the SS, RR-E-Ile to
crystallize, which contributed to a lower overall yield for the SS-analogue.  The amino
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Figure II-5.  1H-NMR spectra of a) S S-E-Ile after 1 recrystallization, b) SS-E-Ile after 6
recrystallizations, c) SR-E-Ile after 1 recrystallization, and d) SR-E-Ile after 6 recrystallizations.
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acids were further purified by multiple recrystallizations to give SS-E-Ile (d.e.
= 95 %) and SR-E-Ile (d.e. = 98 %) as determined by 1H-NMR spectroscopy (Figure II-5).
The preparation of 2-amino-3-methyl-4-pentynoic acid was not stereoselective
and gave a complex mixture of the SS, RR, SR, and RS stereoisomers.  Recrystallization
did not succeed in sufficiently separating SS, RR and SR, RS pairs; final products were ss-
Y-Ile (d.e. = 81%) and ss-Y-Ile (d.e. = 60%) (Figure II-6).
Figure II-6.  1H-NMR spectra of a) SS-Y-Ile (d.e. = 81 %) and b) SR-Y-Ile (d.e. = 60%) after
recrystallization.
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II.4.2 Analogue incorporation
II.4.2.1 SS- and SR-Y-Ile
An E. coli strain rendered auxotrophic for isoleucine was used to assay the extent
of in vivo incorporation of isoleucine analogues into mDHFR, a test protein readily
expressed in bacterial cultures.  SDS-PAGE and Western blotting of the total cellular
protein produced in cultures supplemented with both SS-Y-Ile (d.e. = 81%) and SR-Y-Ile
(d.e. = 60%) indicate expression of target protein (Figure II-7).
In the case of both SS- and SR-Y-Ile, MALDI-TOF mass spectra on tryptic
fragments of mDHFR produced in medium supplemented with the analogue show peaks
with the expected mass difference of -4 for each isoleucine in the peptide (Figure II-8).  It
is clear that we are able to incorporate at least one alkyne analogue into proteins in vivo,
but without more careful purification of the stereoisomers it is impossible to say whether
both or only one of these amino acids is translationally active.
Figure II-7. a) SDS-PAGE and b) Western blot of proteins produced in Ile auxotrophic E.
coli cultures supplemented with the 19 amino acids (lacking Ile) and 1) nothing, or 100 mg/L
of 2) Ile, 3) Ile, 4) SR-Y-Ile, or 5) SS-Y-Ile.  A + indicates induction of mDHFR expression;
expression was not induced in lane 2.  A similar amount of mDHFR is produced in cultures
supplemented with SS-Y-Ile (d.e. = 81 %) and in those containing SR-Y-Ile (d.e. = 60%).
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II.4.2.2 SS- and SR-E-Ile
In cultures supplemented with SS-E-Ile (d.e. = 95 %), SDS-PAGE and Western
blotting again indicate that target protein is expressed in amounts comparable to the
positive control (Ile); in contrast, cultures supplemented with SR-E-Ile (d.e. = 98 %)
yielded significantly less protein (Figure II-9).  This result is consistent with either a low
level of translational activity of SR-E-Ile or with incorporation of residual SS-E-Ile in the
amino acid sample.  As discussed below, we believe the latter interpretation is correct.
MALDI-TOF mass spectra on tryptic fragments of mDHFR produced in medium
supplemented with SS-E-Ile (d.e. = 95%) show signals shifted by the expected mass
difference of -2 for each isoleucine residue in the peptide (Figure II-10).  The MALDI
Figure II-8. MALDI-TOF spectra of tryptic fragments of mDHFR produced in medium
supplemented with a) Ile, b) SS-Y-Ile (d.e. = 81 %), and c) SR-Y-Ile (d.e. = 60 %).  Mass shifts
of –4 per Ile residue in the peptide INIVLSR (residues 86 – 92, m/z = 814.5) in panels b) and
c) indicates incorporation of an alkynyl analogue.
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Figure II-9. a) SDS-PAGE and b) Western blot of proteins produced in Ile auxotrophic E. coli
cultures supplemented with the 19 amino acids other than Ile and 1) nothing, or 130 mg/L of 2)
Ile, 3) Ile, 4) norvaline, 5) Val, 6) SS-E-Ile, 7) SR-E-Ile.  A + indicates induction of mDHFR
expression; expression was not induced in lane 2.  Significantly more mDHFR is produced in
cultures supplemented with SS-E-Ile (d.e. = 95%) than in those containing SR-E-Ile (d.e. = 98%).
Figure II-10. MALDI-TOF spectra of tryptic fragments of mDHFR produced in medium
supplemented with a) Ile, b) SS-E-Ile and c) SR-E-Ile.  Mass shifts of –2 per Ile residue in the
peptide INIVLSR (residues 86 – 92, m/z = 814.5) in panel b) indicate incorporation of SS-E-
Ile.  A lesser extent of incorporation of an unsaturated amino acid is also evident in proteins
produced in culture supplemented with c) SR-E-Ile (d.e. = 98%).
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spectra of fragments of target protein expressed in medium containing SR-E-
Ile (d.e. = 98%) also show evidence of incorporation of an amino acid with a mass
difference of -2.  It is apparent that an unsaturated analogue did replace a fraction of
isoleucine in each of these proteins, but of course it is not possible to distinguish between
incorporation of SS-E-Ile and incorporation of SR-E-Ile from these data.
To determine the identity of the unsaturated amino acid that was incorporated into
mDHFR in experiments with the SR-isomer, we purified protein from large-scale
expressions conducted in medium supplemented with 70 mg/L SR-E-Ile (d.e. = 91%);
protein yield was 4.1 mg/L.  The alkene region of the 1H-NMR spectrum of this protein
(Figure II-11a) is identical to that of a protein expressed in medium supplemented with
SS-E-Ile (d.e. = 76%) (Figure II-11b).  In the amino acid spectra, the multiplet assigned to
the internal alkene proton, Hi, is sensitive to stereochemistry; the chemical shift of this
Figure II-11.  1H-NMR spectra of mDHFR produced in medium supplemented with a)
SS-E-Ile (d.e. = 76%) and b) SR-E-Ile (d.e. = 91%).  Spectra of mDHFR containing only
canonical amino acids show no peaks in this region.
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proton differs by 0.1 ppm for the SS- and SR-isomers.  We find it unlikely that
this resonance would lose its sensitivity to stereochemistry in the protein context.  We
conclude that SR-E-Ile is a poor substrate for IleRS and that it is unable to compete with
residual SS-isomer with respect to in vivo incorporation into proteins under the conditions
used here.
To determine the extent of incorporation of ss-E-Ile, we prepared mDHFR in
cultures supplemented with different levels of the analogue.  SDS-PAGE and Western
blotting of the total cellular protein produced in cultures supplemented with increasing
concentrations of once-recrystallized SS-E-Ile (d.e. = 68 %) indicate increasing levels of
target protein expression (Figure II-12).  Integration of 1H-NMR spectra of mDHFR
produced in large-scale expressions in medium supplemented with 25 mg/L or 125 mg/L
SS-E-Ile (d.e. = 76%) indicate levels of replacement of isoleucine by analogue of 63%
and 72%, respectively.  Protein yields are 12 and 22 mg/L, respectively.
Figure II-12. a) SDS-PAGE and b) Western blot of proteins produced in Ile auxotrophic E.
coli cultures supplemented with the 19 amino acids other than Ile and 1) nothing, 2) 25 mg/L
Ile, 3) 25 mg/L Ile, 4) 25 mg/L ss-E-Ile, 5) 50 mg/L ss-E-Ile, and 6) 125 mg/L SS-E-Ile.  A +
indicates induction of mDHFR expression; expression was not induced in lane 2.  mDHFR is
produced in cultures supplemented with all concentrations of SS-E-Ile (d.e. = 68 %) in this
range.
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II.4.3 Kinetics of Activation of E-Ile by IleRS
The activation of the analogues by IleRS in vitro was investigated by ATP/PPi
exchange.  Interestingly, SS-E-Ile was activated as fast as (or somewhat faster than) the
natural substrate, Ile (kcat/KM = 0.30 µM
-1 s-1) [42], while SR-E-Ile was activated 40-fold
more slowly than Ile (Table II-1).  Because of the ~100-fold difference in the rates of
activation of the SS- and SR-isomers, it not surprising that residual SS-E-Ile in the sample
of the SR-isomer is responsible for the small amount of mDHFR produced in medium
supplemented with SR-E-Ile (d.e. = 98 %).
II.5 Discussion
Incorporation of amino acids analogues into proteins in vivo requires that the
analogues (i) cross the cellular membrane; (ii) be charged to one or more tRNA(s); (iii)
and be delivered to the growing end of the polypeptide chain.  Our work indicates that
none of these steps precludes efficient incorporation of at least one stereoisomer of both
2-amino-3-methyl-4-pentynoic acid (Y-Ile) and 2-amino-3-methyl-4-pentenoic acid (E-
Ile).  In the case of the alkene analogue, we show that the SS-isomer is greatly preferred
Table II-1.  Kinetics of Activation E-Ile by IleRS
analogue Vmax (M s
-1) KM (µM) kcat (s
-1) kcat/KM (µM
-1 s-1) Relative to Ile
SS-E-Ile 2.04 x 10-7 32.9 ± 13 20.35 ± 0.23 0.756 ± 0.32 2.5
SR-E-Ile 4.54 x 10-8 432 ± 101 4.53 ± 0.51 0.026 ± 0.0013 1/40
Ile 2.5 x 10-7 58.2 ± 7.6 17.5 ± 4.5 0.3 ± 0.14 1
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over the SR-isomer by the natural biosynthetic machinery of E. coli; indeed,
we find no conclusive evidence of translational activity for SR-E-Ile.
Following cellular uptake and activation, the analogue must circumvent the
editing pathways that normally limit misacylation of tRNAs.  The selectivity (s) of an
aaRS toward an amino acid is defined as the ratio of the rate of editing to the rate of
activation [21].  The editing mechanism of E. coli isoleucyl-tRNA synthetase (IleRS) has
been extensively studied [43, 44], and its selectivity for natural amino acids is high,
ranging from s = 6000 for valine to s = 8.5 x 106 for alanine [21].  IleRS possesses two
active sites:  a synthetic site for binding of the amino acid prior to activation through
formation of the aminoacyl adenylate and an editing site for removal of amino acids
smaller than isoleucine (which fit into the editing pocket) [22, 23].  The SS-analogues
tested in this study appears to circumvent the editing mechanism of IleRS, possibly
because they are too large to fit into the editing site.
Our results show that IleRS is sensitive to stereochemistry at the β-carbon of E-
Ile; only the SS-isomer of the isoleucine analogue is incorporated into protein at a
measurable rate, and it is activated by the IleRS ~100-fold more rapidly than SR-E-Ile.
This result is in agreement with previous binding studies that demonstrated that L-2-
amino-3S-methylhexanoic acid binds preferentially to IleRS (Ka = 20 mM
-1); its
diastereomer L-2-amino-3R-methylhexanoic acid binds to the enzyme with much a lower
affinity (Ka = 0.6 mM
-1) [45].  It is also consistent with the fact that IleRS distinguishes
L-isoleucine from L-allo-isoleucine [25, 27, 46].  Our data do not preclude the
possibility, however, that discrimination between the SS- and SR-analogues occurs not in
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the synthetic active site of IleRS but rather during some other translational
step, such as editing by IleRS or binding to elongation factor-Tu or the ribosome.
Finally, the efficiency of substitution of SS-E-Ile and Y-Ile for Ile in recombinant
proteins provides a simple and useful method for the incorporation of terminal double
and triple bonds into proteins, giving the chemist access to versatile functional groups in
proteins and protein-based materials.
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CONTROLLED DEGRADATION OF A CELL-ADHESIVE, ELASTOMERIC
PROTEIN THROUGH INCORPORATION OF A FLUORINATED AMINO ACID*
III.1 Abstract
The design of biomaterials with controlled mechanical, cell-adhesive, and
degradative properties is a common goal in tissue engineering and drug delivery systems.
Towards this goal, a series of protein-based biomaterials were synthesized in an
engineered bacterial production system.  These modular proteins include domains from
fibronectin that are known to adhere endothelial cells and elastin-derived repeating units
to provide mechanical integrity.  Fluorination of the protein by in vivo replacement of the
amino acid isoleucine with the noncanonical amino acid 5,5,5-trifluoroisoleucine (5TFI)
resulted in a tenfold decrease in degradation by the enzyme human leukocyte elastase
compared to non-fluorinated protein.  However, even after significant fluorination, the
materials retain their ability to adhere endothelial cells in a sequence-specific manner.
Incorporation of a noncanonical amino acid, without requiring a change in the encoding
genetic sequence, represents a novel strategy to tune the rate of degradation of protein-
based biomaterials without compromising cell adhesion.
*Manuscript prepared for submission by Sarah C. Heilshorn,* Marissa L. Mock,* and
David A. Tirrell.
*These authors contributed equally to this work.
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III.2 Introduction
Genetic engineering techniques allow the templated production of protein
polymers with precisely controlled sequence, molecular weight, and functionality using
microbial biosynthesis.  Such techniques have been employed in the de novo design and
synthesis of engineered proteins with a variety of novel physical and biological activities
[1-8].  These materials have demonstrated potential in tissue engineering and
reconstruction and drug delivery.
Elastin-like domains are of particular interest for engineered, protein-based
biomaterials due to their high expression levels, ease of purification, biocompatibility,
and tunable mechanical properties [9-14].  The extensive work of Urry and coworkers on
the family of elastin-like polypentapeptides (VPGZG)x, where Z is any amino acid,  has
shown that the hydrophobicity of the biopolymer can be used to tune the lower critical
solution temperature (LCST) [15, 16].  Polymers are soluble at temperature below the
LCST but phase separate into a polymer-rich coacervate as the temperature is increased.
This LCST phase transition allows straightforward purification of elastin-like polymers
after biosynthesis using a simple thermal cycling technique.
We have employed this method to purify a set of engineered proteins designed for
use as implantable biomaterials.  The protein sequences (Figure III-1) are a result of a
modular design incorporating domains from fibronectin to adhere endothelial cells [10,
11], which are important for a healthy vasculature, and elastin-like domains to provide
mechanical integrity [17, 18].  Sequence CS5 contains the authentic cell-binding domain,
which adheres human umbilical vein endothelial cells (HUVEC) in a sequence-specific
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manner [11].  As a negative control, sequence SC5 contains a scrambled cell-
binding domain incapable of promoting sequence-specific HUVEC adhesion [19].
Figure III-1.  Amino acid sequences of the engineered proteins.  Each protein has three cassettes
of a cell-binding domain interspersed with an elastin-like domain.  Protein CS5 contains the
authentic CS5 binding domain[11] while SC5 contains a negative control, scrambled domain.
Proteins CS5-F and SC5-F are identical to CS5 and SC5, except they are synthesized in medium
supplemented with 5TFI.
Depending on the specific medical application, e.g., drug delivery or tissue
regeneration, the success of implanted biomaterials will depend on optimization of the in
vivo degradation characteristics.  Often, it is desirable to combine multiple degradation
rates in one material.  For example, a single system could combine rapid delivery of a
pharmaceutical along with sustained release of growth factors for cell infiltration.
Protein-based materials are degraded by a class of enzymes called proteases; however,
native elastin is resistant to many of these proteases with the notable exception of elastase
[20].  Human leukocyte elastase (HLE) is the predominant form of this protease that
circulates the body in the blood stream [21].  HLE preferentially cuts after small,
hydrophobic amino acids, and previous work in our laboratory showed that HLE prefers
to cut after isoleucine in protein CS5 .  We hypothesized that we could alter the
Proteins CS5 (I=isolecuine) and CS5-F (I=5TFI):
M-MASMTGGQQMG-HHHHHHH-DDDDK-{LD-GEEIQIGHIPREDVDYHLYP-G[(VPGIG)2VPGKG(VPGIG)2]4VP}3-LE
Proteins SC5 (I=isolecuine) and SC5-F (I=5TFI):
M-MASMTGGQQMG-HHHHHHH-DDDDK-{LD-GEEIQIGHIPREVDDYHLYP-G[(VPGIG)2VPGKG(VPGIG)2]4VP}3-LE
T7 tag His tag Cleavage
site
CS5 binding domain Elastin-like domain
T7 tag His tag Cleavage
site
Scrambled CS5 binding domain Elastin-like domain
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degradation properties of this engineered protein by replacing isoleucine with
a noncanonical amino acid.
The introduction of functional groups not contained within the 20 canonical
amino acids into proteins is a valuable tool for the protein engineer, providing access to
new chemical reactivity [22-26] and physical properties [27-31].  In many cases it is
desirable to retain the biological activity of a protein upon introduction of these novel
properties, requiring minimal disruption of the active, folded structure and making
fluorinated amino acids of special interest.  While fluorine is similar in size to hydrogen,
the hydrophobicity of the CF3 group is higher than the CH3 group due to the low
polarizability of fluorine [32], giving fluorination of proteins the potential to dramatically
change physical properties of the protein without impairing its biological function [31,
33].  The ability to tune the rate of degradation of a biomaterial by varying the extent of
incorporation of a noncanonical amino acid without requiring a change in the encoding
genetic sequence would provide powerful control in target applications ranging from
drug delivery to tissue engineering.
III.3 Methods
III.3.1 5,5,5-Trifluoroisoleucine (5TFI) synthesis and purification
5TFI was synthesized as previously described [33, 34] with minor modifications.
Stereochemical purity was assessed by HPLC on a CROWNPAK CR (+) chiral column
(Chiral Technologies, Inc.) with 1% perchloric acid/0.3% trifluoroacetic acid as the
mobile phase.  The crude product was a mixture of equal parts of the four stereoisomers
III-5
of 5TFI (D, L-, D-allo, L-allo-5TFI).  It was recrystallized 3 times from 20%
aqueous ethanol; in the final crystals only 1.7 % L-allo-5TFI remained.
The mixture of L- and D-5TFI was acetylated.  D, L-5TFI (2.0 g, 0.013 mol) was
suspended in 7 mL of 2 N NaOH and stirred in an ice bath.  Another portion of 2 N
NaOH (6 mL) and acetic anhydride (0.6 mL) were added.  This addition was repeated 8
times at 2-minute intervals.  The resulting clear solution was kept cold and stirred for 2 h
before being neutralized with 18 mL of 6 N H2SO4.  The solution was extracted with
ether (3 x 50 mL), and the ether was dried over sodium sulfate and evaporated under
vacuum.  The yellow oil obtained was recyrstallized from 1:1 ethyl acetate:hexane,
yielding 1.5 g white, crystalline N-acetyl-D, L-5TFI (74%).
N-acetyl-D, L-5TFI was enzymatically deacetylated to give pure L-5TFI.  The
acetylated amino acid (1.5 g, 0.0098 mol) was dissolved in 400 mL of 100 mM KH2PO4
(pH 7).  Acylase I from porcine kidney (Sigma, 10 mg) was added, and the reaction was
incubated at 37°C and followed by thin layer chromatography (4:1:1 n-butanol:acetic
acid:water) with ninhydrin detection.  When the concentration of free amino acid was no
longer increasing (3 – 4 days), the reaction was acidified to pH 5 with concentrated HCl,
filtered through a 0.22 µm filter, acidified further to pH 2, and extracted with ethyl
acetate (3 x 75 mL).  Evaporation of the ethyl acetate layer gave N-acetyl-D-5TFI.  The
aqueous layer was evaporated under vacuum, and the residue was taken up in methanol
and filtered to remove a large portion of salt.  The methanol was evaporated and the
residue was dissolved in 100 mL of 0.1 N HCl and applied to an ion exchange column
(Dowex 50WX4-100, Sigma).  L-5TFI was eluted with 1 N NH4OH and obtained as a
white powder upon evaporation of the eluent under vacuum (150 mg, 10%).  The final
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product, by HPLC, is 2.7 % L-allo-5TFI and 3.2 % D-amino acid (a mixture
of D-5TFI and D-allo-5TFI, which do not separate under the HPLC conditions
employed).
III.3.2 Protein expression and purification
Proteins CS5 and SC5 were expressed as previously described [11].  To express
proteins CS5-F and SC5-F, a competent isoleucine auxotrophic derivative of E. coli
strain BL21(DE3), designated AI (E. coli B F- ompT hsdS(rB
- mB
-)gal dcm λ(DE3)
ilvD691), constructed in our laboratory [33] and harboring the plasmid pLysS (Qiagen),
was transformed with, respectively, the plasmids pET28-CS5 and pET28-SC5 [17] to
yield strains AI-pET28-CS5 and AI-pET28-SC5.  To express proteins from these strains,
a culture was grown overnight in 2xYT medium and used to inoculate 1 L of M9AA
medium supplemented with the antibiotics chloramphenicol and kanamycin.  At an OD600
of 0.8-1.0, the M9AA cultures were induced by adding 1 mM IPTG.  After 20 additional
minutes of growth, the cells were washed twice with 0.9% NaCl and resuspended in M9
medium containing 19 amino acids (excluding isoleucine) to a final volume of 1 L.  The
cultures were supplemented with 400 mg/L of 5TFI (effectively 100 mg/L of L-5TFI)
and grown for 2 h.  Fluorinated proteins were purified by Ni-affinity chromatography
using Qiagen Ni-NTA agarose resin.  Purity was assessed by SDS-PAGE and Western
blotting with anti-T7 tag-horseradish peroxidase conjugate antibody (Amersham).  Level
of 5TFI incorporation was assessed by amino acid analysis at the University of
California, Davis Molecular Structure Facility (Beckman 6300 amino acid analyzer).
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3.2. Tryptic digest/MALDI
Purified proteins CS5-F and SC5-F were incubated with trypsin (50 mM
ammonium bicarbonate buffer, overnight, room temperature).  The proteolysis products
were purified by eluting from a C18 ZipTip (Millipore) with 75:25 acetonitrile:0.1%
trifluoroacetic acid, spotted on an analysis plate at 4°C, and analyzed by MALDI-TOF
mass spectrometry on an Applied Biosystems Voyager DE Pro instrument.
III.3.3 LCST measurement
The LCST of proteins CS5 and CS5-F was measured at 10 mg/ml in phosphate
buffered saline (PBS), pH 7.4, by increasing the temperature at a rate of 30°C/h and
measuring the percent transmission (measured in volts) at 300 nm on an Aviv model
62DS spectrophotometer (Lakewood, NJ).
III.3.4 Analysis of elastase degradation
For quantification of full-length chains, the degradation reaction was carried out
at 37°C for 3 days in sodium borate buffer, pH 8, with 0.22 µM human leukocyte elastase
(HLE, Elastin Products Company, Owensville, MO) and 100 µM protein.  Samples were
taken at 0, 1, 3, 6, 12, 24, 48, and 72 h and diluted with an equal amount of 2x SDS-
sample buffer with β-mercaptoethanol and frozen at -20°C.  Samples were boiled for 5
min, run on a 12% Tris-tricine gel at 150 V for 1 h, and transferred to poly(vinylidene
fluoride) (PVDF) membrane for Western blot analysis using an anti-T7 tag-horseradish
peroxidase conjugate antibody (Amersham) with a 10 second exposure.  Densitometry
was performed on Western blots using Image J (National Institutes of Health freeware
image analysis program) to quantify the amount of whole-length protein remaining at
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each time point.  Control curves run in parallel indicated a linear relationship
between protein concentration and Western blot intensity for both CS5 and CS5-F
(supporting information, Figure III-8).
For quantification of the number of cleaved peptide bonds, the degradation
reaction was carried out at 37°C in sodium borate buffer, pH 8, with 0.22 µM HLE and
50 µM protein under constant mixing.  The extent of reaction was characterized using
2,4,6-trinitrobenzene sulfonic acid at 4°C to quantify the number of N-termini in solution
at 4 h.
III.3.5 Cell adhesion
Human umbilical vein endothelial cells (HUVEC, Bio Whittaker) were
maintained in a 37°C, 5% CO2 humidified environmental chamber.  The cells were
grown in Endothelial Growth Medium-2 (5% serum, Bio Whittaker), which was replaced
every two days.  Near confluent HUVEC cultures were passaged non-enzymatically by
treatment with 0.61 mM EDTA (Gibco).  Passages 2-5 were used.
Solutions of engineered proteins (1 mg/ml in PBS) and fibronectin (10 µg/ml in
PBS) were adsorbed onto tissue culture polystyrene overnight at 4°C.  Surfaces were
rinsed with PBS, blocked with 0.2% heat-inactivated bovine serum albumin (BSA
fraction V, Sigma) for 30 minutes, and rinsed.
HUVEC in suspension were labeled with a 5-µM solution of calcein
acetoxymethyl ester (Molecular Probes) in serum-free Endothelial Basal Medium (EBM,
Cell Applications, San Diego, CA) at room temperature for 30 min.  Cells were rinsed
twice and resuspended in EBM at 2.67x105 cell/ml.  Cells (150 µl/well) were added to
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adsorbed protein substrates in 96-well plates and incubated for 30 min.  A
solution of 21% w/w PercollTM (Sigma) and PBS was added (200 µl/well) and plates
were centrifuged at 100g for 10 min.  Non-adherent cells were removed using harvesting
frames (Molecular Devices) with the filters removed.  PBS (100 µl/well) was added and
fluorescence was measured using a Perkin Elmer HTS 7000 Bio Assay Reader at an
excitation of 485 nm and emission of 538 nm.  A cell adhesion index was calculated as
the fluorescence reading of a test well divided by the fluorescence reading of HUVEC
attached to fibronectin subjected to 1 g.  The detachment force applied was estimated to
be 26 pN using Archimedes’ theorem [19].
III.4 Results and discussion
III.4.1  Protein synthesis and characterization
Using an engineered bacterial strain, the genetic message encoding the CS5
protein can be alternatively read to produce protein CS5-F, a fluorinated version of CS5.
The high isoleucine content of the CS5 protein permits extensive fluorination through
incorporation of the noncanonical amino acid 5TFI, which has demonstrated levels of
isoleucine replacement from 85 – 93% in bacterial systems [33].  5TFI was prepared as
previously reported [33, 34] and used to express proteins CS5-F and SC5-F with yields
of 0.83 mg/g and 0.71 mg/g wet cell mass, respectively.  Nickel column purification
yielded 5.4 mg pure CS5-F and 3.6 mg pure SC5-F from 1 L shake-flask fermentations.
In contrast, proteins CS5 and SC5 express well and are easily purified using the thermal
cycling technique to provide multi-gram quantities [17, 19].  Typical yields are 2-5 g pure
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protein from 10 L batch fermentations.  Further optimization is required to
synthesize the fluorinated proteins above milligram yields.
To confirm the replacement of isoleucine with 5TFI, the engineered proteins were
digested with the protease trypsin to yield protein fragments of predicted sequence, which
were then analyzed by MALDI-TOF mass spectroscopy (Figure III-2).  The peak at
approximately 2576 Da has been assigned to two proteolytic fragments consisting of
residues 136-161 and 262-286.  These identical fragments contain five potential
isoleucine replacement sites.  Accordingly, the higher mass peaks are assigned to
fragments with incorporation of one, two, three, four, and five 5TFI residues, each with a
shift of 53.88 Da corresponding to the mass difference between isoleucine and 5TFI.
Subsequent amino acid analysis reported 5TFI replacement of 82% of isoleucine residues
2550 2650 2750 2850
+ 1 5TFI
+ 2 5TFI
+ 3 5TFI
+ 4 5TFI
Residues 136-161, 261-286
GVPGIGVPGIGVPLDGEEIQIGHIPR
2576.12
a.
+ 5 5TFI
2550 2650 2750 2850
Residues 136-161, 261-286
GVPGIGVPGIGVPLDGEEIQIGHIPRb.
2576.80
+ 1 5TFI
+ 2 5TFI
+ 3 5TFI
+ 4 5TFI
+ 5 5TFI
Figure III-2.  MALDI-TOF of tryptic digest fragments of a) CS5-F and b) SC5-F.  The
expected mass of the unsubstituted peptide fragments comprising residues 136-161 and
261-286 = 2576.  Peaks are apparent at masses expected for replacement of 1 through 5
isoleucines with 5TFI.
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in CS5-F and 92% in SC5-F.  This is consistent with results from previous
studies demonstrating high incorporation efficiency of 5TFI into recombinant proteins
[33].
We were interested in the effect of fluorination on the thermodynamic phase
behavior of these proteins, as they are commonly purified through thermal cycling [7, 9].
As discussed above, proteins with elastin-like domains are known to exhibit an inverse
temperature transition that is affected by the identity of the amino acid in the Z position
[15, 16, 30, 35].  Relative to the most common pentapeptide repeat in bovine and porcine
elastin, VPGVG [36, 37], the LCST is lowered when the amino acid occupying the Z
position is more hydrophobic than valine and raised when Z is more hydrophilic.  As
expected, introducing the highly hydrophobic amino acid 5TFI into the Z position of the
elastin-like domain results in a decrease of the LCST by more than 20°C (Figure III-3).
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Figure III-3.  Replacement of 82% of the isoleucine residues in CS5 with a fluorinated
amino acid (CS5-F) decreases the LCST by 20°C, as evidenced by the turbidity of a 10
mg/ml in PBS solution, pH 7.4.
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Therefore, the LCST of elastin-like proteins can be tuned by incorporation
of fluorophilic 5TFI side chains, which may aid in optimization of thermal cycling
purification techniques.
III.4.2 Protein degradation
Previous work in our laboratory has identified isoleucine as the favored HLE cut-
site in these engineered, elastomeric proteins (S. C. Heilshorn, P. J. Nowatzki, T.
Yamaoka, and D. A. Tirrell, manuscript in preparation).  Therefore, incorporation of
5TFI into the isoleucine position was explored as a method to enhance HLE resistance.
Due to the low expression levels of CS5-F, full kinetic analysis of the degradation
reaction on the fluorinated protein was not possible.  However, previous research in our
laboratory has demonstrated that degradation of CS5 follows traditional Michaelis-
Menten kinetics with a catalytic constant, kcat, of 0.033 s
-1 and a Michaelis constant, Km,
of 2451 µM (supporting information, Figure 1II-7).  Using these parameters, it is possible
to predict the degradation rate of CS5 and CS5-F, assuming that only the peptide bonds
following isoleucine residues can be cleaved.  The actual number of cleaved bonds in a
reaction mixture can be quantified using 2,4,6-trinitrobenzene sulfonic acid to detect the
concentration of N-termini.  After 4 h of HLE degradation, 90% fewer peptide cleavages
were observed on the fluorinated protein compared to the non-fluorinated protein (Figure
III-4).  These experimental results were in good agreement with the values predicted
using the Michaelis-Menten model, which supports the assumption that HLE can only
cleave peptide bonds following isoleucine in the fluorinated elastomer.
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Figure III-4.  HLE degradation of CS5-F produces 90% fewer new N-termini per original
molecule than CS5 after 4 h of reaction.  Observed data represent two independent experiments,
both testing three replicates of each substrate; error bars represent one standard deviation.
Predicted data are based on the assumption that the reactions follow Michaelis-Menten kinetics
and only the peptide bonds following isoleucine residues can be cleaved.
To examine the time course of degradation of CS5 and CS5-F, Western analysis
was used to determine the amount of full-length, intact protein remaining after HLE
exposure for various times, and densitometry was employed to quantify the percent of
full-length protein remaining at each time point (Figure III-5).  Incorporation of 5TFI into
the elastin-like protein significantly inhibited elastase activity.  At 6 h, 46% of CS5-F
remained intact, compared to 0% of CS5.  Furthermore, full-length CS5-F was still
detectable after 24 h exposure to HLE.  Similar to the analysis performed above, the
degradation reaction rates can be predicted using the Michaelis-Menten parameters for
peptide cleavage after isoleucine residues.  Using the simple assumption that each peptide
cleavage results in the loss of one full-length protein chain, the predicted degradation
rates for CS5 and CS5-F are in good agreement with the observed values.
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Figure III-5.  HLE degradation of protein was monitored by Western blot and quantified using
densitometry analysis of CS5 () and CS5-F () protein.  No full-length CS5 was observed
after 6 h, while nearly half of CS5-F is still intact. The rate of chain degradation was predicted for
CS5 (dashed line) and CS5-F (solid line) using Michaelis-Menten parameters for the cleavage of
peptide bonds after isoleucine residues.
III.4.3 Endothelial cell adhesion
We also investigated the ability of the fluorinated proteins CS5-F and SC5-F to
promote cell adhesion.  CS5 was previously reported to be adherent to HUVEC in a
sequence-specific manner [11].  Such adhesion is mediated through interactions with the
REDV minimal binding sequence within the CS5 cell-binding domain.  We wished to
confirm that sequence-specific HUVEC adhesion would not be compromised by
significant fluorination of the elastin-like regions.  The ability of these engineered
proteins to adhere HUVEC was examined using a buoyant centrifugation assay (Figure
III-6).  At a detachment force of 24 pN, protein CS5-F exhibited HUVEC adhesion
greater than that of protein CS5 and negative control proteins SC5-F and SC5, which
contain scrambled cell-binding domains.  Adhesion to fibronectin, which contains
multiple cell-binding domains, was included as a positive control.
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Figure III-6.  Percent of HUVEC remaining adherent to adsorbed fibronectin and engineered
proteins after 10 min exposure to 24 pN detachment force (100 g) relative to HUVEC remaining
on adsorbed fibronectin after 10 min exposure to 0.24 pN (1g).  Data represent three independent
experiments in which six replicates of each substrate were tested; error bars represent one
standard deviation.
These results suggest that 5TFI incorporation into these artificial proteins does not
inhibit sequence-specific HUVEC binding.  Therefore, fluorination of this engineered
protein can successfully alter the thermodynamic behavior and proteolytic susceptibility
without impairing the desired biological activity.  While the observed increase in
HUVEC adhesion to the fluorinated protein CS5-F relative to the non-fluorinated protein
CS5 is interesting, these results require further investigation.  Ongoing research in our
laboratory has shown similar context-dependence of adhesion strength to engineered
proteins containing the CS5 domain.
We have demonstrated the ability to control the rate of proteolysis of elastin-like
biomaterials through the incorporation of a noncanonical amino acid.  From a single
genetic message, two protein-based materials with varying degree of fluorination were
created.  Fluorination of the engineered elastomer retards elastase degradation of the
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protein while also altering the thermodynamic phase behavior.  The ability
of the material to adhere endothelial cells through the sequence-specific interaction with
the CS5 cell-binding domain is unaffected.  Residue-specific incorporation of
noncanonical amino acids into proteins is an additional tool for the biomedical engineer
in the attempt to precisely control the material properties and biological activity of
protein-based biomaterials.
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III.5 Supporting information
Figure III-7.  Kinetic analysis of HLE degradation of CS5.  Error bars represent a 90%
confidence interval.  The dashed line represents a best fit of the observed data to the Michaelis-
Menten kinetic model.
Figure III-8.  Control curves for densitometry analysis of Western blots for CS5 () and CS5-F
() with best-fit lines.  Band intensity showed a linear increase with concentration up to 1 mM
for both proteins.
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LITHOGRAPHIC PATTERNING OF AN INTRINSICALLY PHOTOREACTIVE
CELL-ADHESIVE PROTEIN*
IV.1 Abstract
This chapter describes a novel, simple method for the photolithographic
patterning of cell-adhesive proteins.  Intrinsically photoreactive proteins are synthesized
in Escherichia coli (E. coli) through incorporation of the noncanonical photoactive amino
acid para-azidophenylalanine.  Upon ultraviolet irradiation at 365 nm, proteins form
crosslinked films with elastic moduli that can be tuned by varying the concentration of
photoreactive amino acid in the expression medium.  Films of these proteins can be
directly patterned using standard photolithographic techniques.  Processing of irradiated
films is performed under mild aqueous conditions, allowing these proteins to retain
biological activity.  We demonstrate the utility of this method of protein patterning by
creating stable arrays of endothelial cells on an engineered protein “photoresist.”
*Reproduced in part with permission from the Journal of the American Chemical Society,
submitted for publication:  Isaac S. Carrico, Sarah C. Heilshorn, Marissa L. Mock, Julie
C. Liu, Paul J. Nowatzki, Stacey Maskarinec, Christian Franck, Guruswami
Ravichandran, David A. Tirrell, Lithographic Patterning of Intrinsically Photoreactive
Cell-Adhesive Proteins.  Unpublished work copyright 2005 American Chemical Society.
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IV.2 Introduction
Control of the spatial arrangement of proteins on surfaces is an essential factor in
a number of emerging biotechnologies.  Defining the location of specific proteins on the
micro- or nanoscale improves the quality of protein microarrays, increases the sensitivity
of biosensors [1, 2], and allows tissue engineering scaffolds to interact with multiple cell
types [3].  Patterning is also a powerful tool in cell biology, where cell arrays are used to
elucidate key factors that mediate migration, growth, and cell-cell interactions [4-6].
Although photolithography holds a preeminent place as a method to create
patterns in the microelectronics industry, optical lithography of proteins has been
hampered by the need either to use traditional chemical photoresists or to modify proteins
chemically by attachment of photoactive functional groups; both methods can
compromise protein function [7].  To circumvent these issues, new techniques such as
microcontact printing and dip-pen nanolithography have emerged that allow direct
placement of adhesive proteins or peptides on a surface [8, 9].  Despite these advances,
the hallmarks of photolithography — high registry, throughput, and fidelity — are not yet
matched by current methodologies.
Production of a protein “photoresist” without the need for post-translational
chemical modification would require an intrinsically photoreactive protein.  Recently, the
incorporation of photoreactive noncanonical amino acids into proteins has been reported
using both site-specific [10, 11] and residue-specific techniques [12].  Here we describe
the microbial expression of artificial protein bearing the photosensitive noncanonical
amino acid para-azidophenylalanine (pN3Phe).  Aryl azides have been previously shown
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to mediate crosslinking efficiently in sensitive biological systems [13].  The
recombinant proteins, designated artificial extracellular matrix proteins with aryl azides
(aECM-N3), belong to a family of engineered proteins designed to exhibit mechanical
properties similar to those of native elastins [14], and to support adhesion of endothelial
cells through a cell-binding domain derived from the CS5 region of fibronectin (Figure
IV-1a) [15].  We demonstrate that these proteins can be efficiently crosslinked upon
irradiation at 365 nm.  The physical properties of the crosslinked films can be tuned by
changing the extent of pN3Phe incorporation, which is accomplished simply by changing
the concentration of the noncanonical amino acid in the expression medium.
Furthermore, thin films of such proteins can be patterned on surfaces using simple
photolithographic techniques.  We demonstrate the utility of the method by creating cell
arrays through endothelial cell attachment to lithographically prepared protein patterns.
IV.3 Methods
IV.3.1 Protein expression
Samples of aECM-N3 were expressed using a phenylalanine auxotrophic
derivative of E. coli strain BL21(DE3), designated AF-IQ [16] and harboring the plasmid
pNS-CS5-ELF [17], which encodes both the desired aECM sequence and the phes* gene
for the A294G mutant E. coli PheRS.  To express proteins from these strains, a culture
was grown overnight in 2xYT medium and used to inoculate 1 L of M9AA medium
supplemented with the antibiotics chloramphenicol and kanamycin.  At an OD600 of 1.0,
expression of target protein and T7 RNA polymerase was induced by adding 1 mM
IPTG.  After 10 additional minutes of growth, the cells were washed twice with 0.9%
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NaCl and resuspended in M9 medium containing 19 amino acids (excluding
phenylalanine) to a final volume of 1 L.  The cultures were supplemented with either 25
mg/L phenylalanine (positive control) or up to 250 mg solid pN3Phe and grown for 4 h.
Protein expression was monitored by SDS-PAGE and Western blotting with anti-T7 tag-
horseradish peroxidase conjugate antibody (Amersham).
IV.3.2 Protein purification
The aECM-N3 protein was purified using a modified temperature cycling
procedure previously described for elastin-containing aECM constructs [18, 19].
Expression cultures were pelleted at room temperature (10000g, 10 min, 25°C),
resuspended in 20 mL of TEN buffer (10 mM Tris, 1 mM EDTA, 0.1 M NaCl) by
sonication with a probe sonicator, and frozen at –20°C.  To frozen lysate, 1 mM PMSF
and 10 µg/mL each of DNase and RNase was added.  This mixture was agitated for 4 h at
37°C and then centrifuged at room temperature (22000g, 60 min, 25°C), which is above
the expected lower critical solution temperature of aECM-N3.  The target protein was
extracted from the pellet by stirring overnight in 4 M urea at 4°C.  This suspension was
centrifuged (22000g, 60 min, 2°C), and the supernatant was dialyzed in 12-14 kD
MWCO dialysis tubing against cold (4°C) distilled water for three days with six water
changes.  Precipitate formed during dialysis was removed by centrifugation (22000g, 60
min, 2°C).  The supernatant, which contained aECM-N3, was lyophillized.
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IV.3.3 1H-NMR of aECM-N3
Purified aECM-N3 proteins were lyophilized completely and dissolved in DMSO-
d6 at 40 mg/mL.  Spectra were collected on a Varian Inova NMR spectrometer with
proton acquisition at 599.69 MHz
IV.3.4 FTIR spectroscopy
Infrared spectra were taken using a Perkin Elmer 1600 series FT-IR.  Protein
samples were drop-cast onto zinc selenide wafers from DMSO. To measure azide
decomposition kinetics, a 10% aECM-N3 solution in DMSO was spun onto a ZnSe
crystal at 2000 rpm for 100 seconds.  The resulting film was dried for 2 minutes at 50°C.
Films were irradiated at 365 nm through at transparent mask in a Karl Suss mask aligner
to mimic the protein lithography conditions.  Infrared spectra were taken of the irradiated
film at various time points until the azide peak was no longer changing.
IV.3.5 Mechanical testing of bulk films
Flims were prepared by drying aECM-N3 solutions (10 wt % in DMSO) at 50°C
overnight in Teflon molds followed by irradiation for 30 s approximately 8 inches from
an unfiltered Oriel 100W medium pressure mercury lamp.  The crosslinked samples were
removed from the mold and immersed in 4°C water overnight to fully hydrate.  Swollen
flims were cut into testing strips of approximately 3 mm x 10 mm.
Tensile testing was performed using an Instron device with a constant strain rate
of 10 % per minute on films equilibrated in a bath of PBS buffer at 37°C.  Elastic
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modulus (E) was obtained from the slope of the steepest part of the initial
plot.  Each protein sample was tested 3-6 times.
IV.3.6 Preparation of aminated glass surfaces
Glass coverslips were sonicated for 15 min in a saturated solution of potassium
hydroxide in ethanol.  Clean coverslips were rinsed under a stream of filtered (0.2 µm)
doubly distilled water followed by a stream of ethanol, dried briefly with canned air, and
then dried at 50°C for 30 min.  Dried coverslips were immersed for 30 min in a freshly
prepared solution of 1 mL 3-(trimethoxysilylpropyl)diethylenetriamine (DETA), 2.5 mL
acetic acid, and 46.5 mL filtered water (2 % DETA in 5% acetic acid).  Aminated
coverslips were rinsed under a stream of water, rinsed under a stream of ethanol, dried
with canned air, and cured for 4 h at 50°C.
IV.3.7 Preparation of PEG-modified slides
Aminated coverslips were placed in a covered dish containing a reservoir of
pyridine.  The coverslips were covered dropwise with a 100 mM solution of PEG-SPA-
5000 (Nektar Therapeutics) in pyridine.  After 12 h, the PEGylated coverslips were
rinsed under a stream of water, rinsed under a stream of ethanol, dried with canned air,
and used immediately.
IV.3.8 Spin coating of protein films
A 12.5 mg/mL solution of aECM-N3 in DMSO was centrifuged for 1 min at
14000 rpm.  This solution was added dropwise to cover the top of a PEGylated 12 mm
circle glass coverslip (~8 µL). The coverslip was spun for 100 s at 1400 rpm on a
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Specialty Coating Systems model P-6000 spin coater.  Protein-coated slides
were dried at 50°C for 30 min.  Exposure of protein to sunlight was avoided until protein
photolithography was complete.
IV.3.9 Protein lithography
Protein-coated slides were exposed for 30 s in a Karl Suss mask aligner (365 nm)
under a chrome-on-quartz mask prepared by Dr. Michael Diehl at the California Institute
of Technology by chrome deposition and stripping from a 3000 dpi transparency [20].
Irradiated slides were washed overnight in 0.05 % sodium dodecyl sulfate (SDS) to
remove uncrosslinked protein from the masked regions and then rinsed for 6 h in doubly
distilled, filtered water.
IV.3.10 Cell culture
Human umbilical vein endothelial cells (HUVEC) were purchased from Clonetics
and maintained in endothelial growth medium-2 (EGM-2, 2% serum, Clonetics,
Walkersville, MD).  Cells were kept in a humidified, 5% CO2 environment at 37°C and
passaged non-enzymatically using a 0.61 mM EDTA solution (Gibco, Grand Island, NY).
Cells between passages 3 and 8 were used for all experiments.
All coverslips were sterilized by immersion in a 75% aqueous ethanol solution for
at least 2 min and then dried using canned air.  Substrates were placed in sterile 6-well
polystyrene culture plates and blocked with a solution of 2% heat-denatured BSA in PBS
for 30 min.  For cell patterning studies, freshly harvested HUVEC cells were plated on
the prepared substrates at a density of 4.2 x 104 cells/cm2.  Cell viability was measured
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using a standard Wst-1 assay and cell adhesion was quantified using the
buoyant centrifugation method described in Liu and coworkers [21].
IV.3.11 Phase contrast and fluorescence microscopy
Phase contrast pictures were taken on a Nikon Eclipse TE 300 microscope.
Fluorescence pictures were taken on a Zeiss Axioplan II fluorescence microscope
equipped with a monochrome Axiocam.  To fix and fluorescently label cell patterns, the
coverslips were placed in a 6-well plate, and each well was washed 3 times with 2 mL
PBS before 1 mL ice-cold acetone was applied for exactly 1 min.  The wells were again
washed 3 times with 2 mL PBS before 2 mL of a 10% BSA solution was applied for 30
min at room temperature.  After blocking, 0.2 µL of anti-T7 primary antibody (Novagen)
was added and allowed to incubate at room temperature for at least 6 h.  The wells were
then washed three times with 2 mL PBS for 5 min without agitation.  A secondary
antibody/phalloidin solution composed of 862 µL PBS, 100 µL secondary antibody (Cy2-
labeled anti-mouse, 0.5 mg/mL, Chemicon) and 38 µL rhodamine-phalloidin (Molecular
Probes) was incubated with the samples in the dark for 1 h.  Labeled samples were
washed with 2 mL PBS for 10 minutes with agitation followed by 2 mL PBS for 5
minutes without agitation.  The samples were then incubated with 1 mL of DAPI solution
(0.3 µM in PBS) for 5 minutes at room temperature.  Samples were rinsed 3 times with 2
mL PBS and mounted to a glass slide using filtered mounting solution of 1:1
PBS:glycerol and clear fingernail polish as sealant.
IV.3.12 Atomic force microscopy
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Atomic force microscopy was conducted on dried, patterned aECM-
N3 protein films on PEGylated coverslips in constant-force, non-contact mode with an
autoprobe M5 atomic force microscope (Parker Scientific).
IV.4 Results and Discussion
Large-scale production of the aECM-N3 protein was accomplished through
residue-specific incorporation of pN3Phe in E. coli.  This method of incorporation relies
on competitive activation of phenylalanine and pN3Phe by the phenylalanyl-tRNA
synthetase, the enzyme responsible for charging phenylalanine to its cognate tRNA.  The
phenylalanyl-tRNA synthetase used for this study was a previously characterized mutant
with relaxed substrate specificity [12, 22].  Proteins were expressed in a phenylalanine-
auxotrophic E. coli strain grown in cultures supplemented with pN3Phe and purified by
taking advantage of the inverse temperature phase behavior of proteins with elastin-like
repeats [23].  Incorporation efficiency was determined by integration of the aromatic
proton signals in the 1H NMR spectra of the purified proteins (Figure IV-1b); the extent
of phenylalanine replacement varied from 13% to 53% depending on the concentration of
pN3Phe in the expression medium (Figure IV-2).
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Figure IV-1.  Design and production of aECM-N3.  (a) The aECM-N3 primary sequence encodes
a cell-binding domain (the CS5 region of fibronectin) and a structural domain (the pentapeptide
VPGVG elastin-like repeat with periodic phenylalanine sites for incorporation of pN3Phe).  (b)
1H NMR (600 MHz, DMSO-d6) of the artificial protein expressed in the presence of
phenylalanine (bottom spectrum) or in the presence of 250 mg/L pN3Phe (top spectrum).
Integration indicates 53% pN3Phe incorporation.
MMASMTGGQQMGRKTHHHHHHMG{LDGEEIQIGHIPREDVDYHLYPG[(VPGVG)2(VPGFG)(VPGVG)2]5LP}3LE
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Understanding the response of the designed photoreactive protein to irradiation is crucial
for high-resolution pattern formation.  We measured the rate of azide decomposition
under irradiation by monitoring loss of the characteristic infrared (IR) asymmetric stretch
at 2130 cm-1 (Figure IV-3a) [24].  Measurements were performed on thin films of aECM-
N3 spin-coated directly onto zinc selenide wafers and irradiated using a Karl Suss contact
aligner filtered to 365 nm in constant intensity (7 mW/cm2) mode, with a quartz wafer in
place of the mask.  Azide loss under these conditions was rapid, following first-order
kinetics with a half-life of 34 seconds (Figure IV-3b).  It is noteworthy that none of the
other infrared bands were noticeably altered, implying that irradiation under the
conditions used here specifically affects the aryl azide without substantial modification of
any of the canonical amino acids.  This is expected given that none of the canonical
amino acids absorb above 310 nm [25].
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Figure IV-2. Incorporation of pN3Phe into aECM-N3 as a function of concentration in the
expression medium.
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Elastic moduli of irradiated aECM-N3 bulk films were determined through
uniaxial tensile testing under physiological conditions (Figure IV-3c).  As expected, the
elastic modulus correlated with the extent of pN3Phe incorporation.  Irradiated aECM-N3
films in which 30, 41, and 53% of the encoded phenylalanine residues were replaced with
pN3Phe yielded elastic moduli of 0.53 ± 0.10, 0.94 ± 0.09, and 1.39 ± 0.09 MPa, which
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Figure IV-3.  Characterization of azide decomposition by infrared spectroscopy and
mechanical photocrosslinked films.  (a) FT-IR spectrum of aECM-N3 films as a function
of irradiation time in the region of the aryl azide asymmetric stretch.  Irradiation times are
0 (bottom), 0.5, 8, 24, 88, and 124 seconds (top).  (b) Peak area versus irradiation time
yields a first order exponential decay. (c) Uniaxial tensile testing of aECM-N3 films with
variable pN3Phe incorporation.
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are in the range of native elastin (0.3 – 0.6 MPa) [26].  Replacement of less
than 20% of the encoded phenylalanine residues gave films that were too weak to test,
and films made without pN3Phe yielded no evidence of crosslinking.  The fact that the
modulus can be controlled simply by changing the pN3Phe concentration in the
expression medium is an attractive feature of the method, as recent work has highlighted
the role of mechanical transduction mechanisms in mediating the physiology of adherent
cells [27, 28].
To investigate the potential of our photoreactive proteins as substrates for studies
of cell adhesion and growth, we created patterns of adherent endothelial cells on proteins
patterned by photolithography.  Protein films created by spin-coating 12.5% solutions of
protein in dimethylsulfoxide directly onto prepared poly(ethylene glycol) (PEG)-coated
glass coverslips were clear and homogeneous by optical microscopy.  These protein films
irradiated for 30 seconds at 365 nm through a chrome-on-quartz mask using a Karl Suss
contact aligner.  Stripping of the masked areas was accomplished by washing in mild
aqueous detergent (0.05% aqueous sodium dodecasulfate).
Fluorescence immunolabeling with anti-T7-tag IgG antibody revealed that the
aECM protein was localized only within the irradiated areas of the pattern (Figure IV-4a).
Films prepared from protein lacking pN3Phe formed no detectable patterns even after
prolonged exposure times.
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Figure IV-4.  Characterization of photopatterned aECM-N3 features by fluorescence and atomic
force microscopy. (a) Fluorescence microscopy of photopatterned aECM-N3.  PEGylated glass
slides were spin coated with aECM-N3, irradiated for 30 seconds, and washed overnight in 0.05%
SDS to produce well-defined protein features on a non-adhesive background.  Protein patterns
were immunolabeled with an anti-T7-tag primary antibody and an anti-mouse Cy2-conjugated
secondary antibody. (b) AFM image of patterned aECM-N3.  The image was taken of a dried
aECM-N3 patterned film in constant-force, non-contact mode with an autoprobe M5 atomic force
microscope.
a.
b.
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The edge roughness of protein pattern features is a consequence of
the roughness of the mask (created from a 3000 dpi print) and not the inherent resolution
of the films (Figure IV-5). Non-contact AFM of dried aECM-N3 patterns demonstrated
uniform features, which varied in height depending upon the conditions used for spin
coating.  Films spun at 1400 rpm were 84 nm thick (Figure IV-4b), whereas those spun at
2000 rpm were approximately 4 nm thick.  Protein patterns stored either dry or in
aqueous solutions were stable for weeks.
Figure IV-5. Phase contrast images of the chrome mask used in photopatterning (left
panels) compared with fluorescence microscopy images of the protein patterns (right
panels).  Scale bars represent 50 microns.  In the top panels (lower magnification), the
protein pattern could be visually matched to precisely the region on the mask that created
it.  The bottom panels (higher magnification) show two separate regions with features of
similar sizes.
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To create cell arrays, HUVEC were plated on aECM-N3 patterns in
the absence of serum.  After six hours of incubation, the medium was supplemented with
2% serum.  After 24 hours of incubation, HUVEC exhibited a well-spread morphology
(Figure IV-6a) and had proliferated to confluence exclusively within the patterned areas
(Figure IV-6b).  HUVEC monolayers in the interior of the patterned regions displayed
morphology indistinguishable from monolayers grown on homogenous fibronectin
coatings; however, HUVEC positioned along the aECM-N3 pattern edges were elongated
and oriented parallel to the pattern border (Figure IV-6a), consistent with previous
studies.  As expected, actin stress fibers within these elongated cells were aligned with
the pattern edges (Figure IV-6b).  Similar to other endothelial cell patterning techniques,
this parallel cell alignment was generally observed for the first two to three cell layers
adjacent to the pattern edges; therefore, cell alignment was enhanced on patterns with
smaller feature sizes [29].
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Figure IV-6. (a) Phase contrast and (b) fluorescence microscopy of HUVEC attached to
photopatterned aECM-N3.  Cells were plated onto the prepared surfaces in serum free media and
allowed to incubate 6 hours prior to supplementation with 2% serum.  After 24 hours, the cells
and substrates were fixed with acetone, immunolabeled with an anti-T7-tag primary antibody and
anti-mouse Cy2-conjugated secondary antibody, and stained with phalloidin (specific to the actin
cytoskeleton) and DAPI (specific to the nucleus).
a.
b.
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In serum, HUVEC patterns were stable for 48 hours after reaching
confluence, consistent with known behavior of PEG coatings as cell-resistant
backgrounds [30].  At longer times, cells began growing beyond the protein pattern at the
corners, probably in concert with synthesis and secretion extracellular matrix proteins.
The availability of intrinsically photoreactive proteins enables a facile new
method for the patterning of proteins and cells.  The technical simplicity of the method
allows rapid production of samples with a variety of feature shapes and sizes, while
permitting straightforward engineering of the elastic modulus of the crosslinked protein.
The method represents a promising new approach to the study of adherent cells by
providing exquisite control over mechanical properties, ligand-receptor interactions, and
geometric shape.  Applications in medical devices, tissue engineering, and array
technologies are readily imagined.
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PROGRESS TOWARD CLONING THE GENE OF AN RGD-CONTAINING
PROTEIN FOR PHOTOPATTERNING*
V.1 Abstract
We have previously described a new method for the production of cell-adhesive
photolithographic protein patterns (Chapter 4) using the noncanonical amino acid p-
azidophenylalanine (pN3Phe).  We demonstrated the procedure using an artificial
extracellular matrix (aECM) protein [1] containing the CS5 cell-binding sequence
derived from the IIICS region of fibronectin that is known to selectively adhere
endothelial cells [2].  Previous work in our group has shown that endothelial cells attach
both more quickly and strongly to an aECM protein containing an RGD-based sequence
[3] from the CCBD of fibronectin [4].  We wished to create an expression strain
harboring a plasmid encoding the artificial gene for an RGD-based sequence with
phenylalanine residues within the elastin-like domain, which would permit
photopatterning through the incorporation of pN3Phe.  The cloning strategy and progress
toward the final construct will be described in this chapter.
*This work was performed with Stacey Maskarinec.
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V.2 Introduction
As described in Chapter 4, we have recently demonstrated that incorporation of
the noncanonical amino acid p-azidophenylalanine (pN3Phe) into a protein, dubbed
artificial extracellular matrix protein with aryl azides (aECM-N3), permits patterning of
the protein on a surface using traditional photolithographic techniques.  Further, we used
this technique to create cell patterns through selective attachment of human umbilical
vein endothelial cells to the aECM-N3 protein, which contains a known endothelial cell-
binding domain, when patterned on a non-adhesive background of poly(ethylene glycol)
(PEG).
The sequence of the aECM-F protein we studied (Figure V-1) contained elastin-
like repeats to provide structural integrity, regular Phe residues within the elastin-like
regions as sites of crosslinking, and repeats of a cell-adhesive sequence (CS5) derived
from the IIICS region of fibronectin that is known to adhere endothelial cells but not
MMASMTGGQQMGHHHHHHMG(LD-GEEIQIGHIPREDVDYHLY-PG((VPGVG)2VPGFG(VPGVG)2)5VP)3-LE
MASMTGGQQMGHHHHHHMKL{LDASFLD-YAVTGRGDSPASSKPIA-ASA[(VPGVG)2VPGFG(VPGVG)2]5VP}3LE
MASMTGGQQMGHHHHHHMKL{LDASFLD-YAVTGRDGSPASSKPIA-ASA[(VPGVG)2VPGFG(VPGVG)2]5VP}3LE
MASMTGGQQMGHHHHHHMKL{LDASFLD-GEEIQIGHIPREVDDYHLY-ASA[(VPGVG)2VPGFG(VPGVG)2]5VP}3LE
CS5-F:
SC5-F:
RGD-F:
RDG-F:
Figure V-I.  Amino acid sequences of the artificial extracellular matrix proteins.  The CS5-F
protein was previously cloned by Nandita Sharma [1] and is discussed in Chapter 4.  The target
proteins for cloning are a construct containing a different cell-binding domain (RGD-F) and the
negative control proteins for both cell-binding domains (RDG-F and SC5-F).
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fibroblasts, platelets, or smooth muscle cells [2].  We will refer to this
construct as CS5-F.  Previous work in our laboratory on similar constructs (lacking Phe
residues) [3] showed that endothelial cells form stronger attachments and form them
more quickly when aECM proteins with repeats of an RGD-containing sequence derived
from the CCBD region of fibronectin [4] are used.  We wished to create an expression
strain harboring a plasmid copy of the artificial gene for the RGD-containing version of
the aECM protein we used previously.  We also undertook to clone the appropriate
negative control proteins for both the CS5-F and RGD-F sequences; these are designated
SC5-F and RDG-F, respectively.  The set of proteins is generically designated CBD-F for
cell-binding domain construct with Phe residues.  The sequences of the CBD-F (Figure
V-1) proteins were designed based on CS5-F to contain repeats of the appropriate cell-
binding domains as well as regular Phe residues within the elastin-like regions to permit
photocrosslinking.
V.2.1 Cloning strategy
The cloning strategy to obtain this sequence (Figure V-2) was based on one
developed by Liu and Tirrell [5].
Synthetic DNA oligonucleotides encoding the desired CBDs (Figure V-3) were
designed and ordered commercially.  Phosphorylated oligonucleotides were ligated into
the pUC19 vector at the EcoR I / BamH I sites.  The cell-binding domain regions were
cut out of the pUC19-SC5, pUC19-RGD, or pUC19-RDG vectors with EcoR I / BamH I
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pUC19
CBD oligo
ligase
Eco RI
Bam HI
pUC19-CBD
Eco RI
Bam HI
pEC2
Eco RI
Bam HI
ligase
pEC2-CBD
Ban I
CIP
pUC19-ELF
Ban I
ligase
ELF5
ligase
Sal I
Xho I pEC2-CBD-ELF5
CBD-ELF5
CBD-ELF5
Xho I
CIP
pET28cylPheRS* ligase pET28cylCBDELF5
Xho I
CIP
Xho I
CIP
ligase
ligase
ligase
Sph I
CIP
pET28cyl
PheRS*
pET28cylCBDELF5
ligase
Nhe I
CIP
CBD’
pET28cylCBD’ELF5
Figure V-2.  The cloning strategy for CBD-F proteins.
I.
II.
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digestion and ligated into Ban I-linearized pEC2 vector [6] to produce pEC2-SC5, pEC2-
RGD, and pEC2-RDG.
ELF monomer (Figure V-4) was obtained through Ban I digestion of pUC19-ELF
[1].  The 75-bp fragment was multimerized through ligation with T4 DNA ligase, and the
multimerization mixture was run on a 2% agarose gel.  The band corresponding to
pentamer (375 bp) was cut out and extracted from the gel.  The pentamer DNA was
ligated into pEC2-SC5 vector that had been digested with Ban I and dephosphorylated
with CIP to yield pEC2-SC5-ELF5.
Figure V-3.  DNA oligonucleotide sequences encoding a) the RGD cell-binding domain
and b) the scrambled RDG and c) scrambled REVD negative control domains were
designed and ordered commercially.
a)
b)
c)
V-6
Meanwhile, the gene encoding the A294G mutant PheRS (phes*) was cut from
pUC19-FS [1] with Sph I.  It was ligated into the Sph I site of pET28cyl [5] to create
pET28cyl-phes*.  The pEC2-SC5-ELF5 vector was digested with Xho I / Spa I, but
attempts to ligate it into the pET28cyl-phes* failed.  Sequencing revealed a second Xho I
site on the pET28cyl-phes* between the Sph I ligation site and the start of the phes* gene.
Future work will focus on removing this cut site through site-directed mutagenesis.
V.3 Methods
V.3.1 pET28cyl-phes*
The phes* gene was isolated from pUC19-FS [1] through digestion with Sph I
(NEB).  It was ligated using T4 DNA ligase (NEB, room temperature, overnight) into
pET28cyl [5] that had been linearized with Sph I (37°C, overnight) to produce pET28cyl-
phes*.  The A294G mutation was confirmed through DNA sequencing.
V.3.2 pEC2-RGD, RDG, and SC5
The cell-binding domain oligonucleotides (Figure V-4) were ordered from Qiagen
and resuspended at 5 µg/µL in 10 mM Tris buffer at pH 8.1.  A 10-µL aliquot of each
strand was added to 80 µL of annealing buffer (100 mM NaCl, 20 mM MgCl2) and
Figure V-4.  DNA and protein sequence of the ELF monomer digested from pUC19-ELF.
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heated to near boiling for 2 to 3 minutes.  The solution was allowed to cool
slowly back to room temperature and run on a 2 % agarose gel.  The bands corresponding
to the expected DNA (SC5 = 105 bp, RGD and RDG = 99 bp) were cut from the gel and
extracted using a QIAquick Gel Extraction Kit (Qiagen).
The cell-binding domain fragments were phosphorylated using T4 polynucleotide
kinase (NEB).  Purified DNA was incubated at 37°C for 2 h with kinase in the supplied
kinase buffer.  The phosphorylated cell-binding domains were ligated (T4 DNA ligase
[NEB], room temperature, 2 h) into pUC19 vector [1] that had been digested at 37°C
overnight with EcoR I (NEB) and BamH I (NEB).  The pUC19-RGD, RDG, and SC5
vectors were transformed into XL-1 Blue competent cells (Stratagene).
The XL-1 Blue strains harboring the plasmids pUC19-RGD, RDG, and SC5 were
grown in 5 mL overnight 2xYT cultures, and the plasmid DNA was isolated using a
Miniprep Kit (Qiagen).  The vectors were digested at 37°C overnight with EcoR I and
BamH I, the digestion mixtures were run on a 2 % agarose gel, and the appropriate cell-
binding domain fragments were excised and extracted using a QIAquick Kit.  Purified
fragments were ligated into pEC2 plasmid [7] that had been digested with EcoR I and
BamH I to create pEC2-RGD, RDG, and SC5.
V.3.3 pEC2-SC5-ELF5 and ELF6
The DNA fragment encoding one repeat of the desired elastin-like region with
Phe sites, designated ELF (Figure V-5), was obtained through digestion of pUC19-ELF
(Nandita Sharma).  The plasmid DNA was isolated from a 500-mL overnight 2xYT
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culture using a MaxiPrep Kit (Qiagen) and digested at 37°C overnight with
Ban  I (NEB).  The digestion mixture was run on a 3 % agarose gel, the band
corresponding to ELF monomer (75 bp) was excised, and the DNA was extracted with a
Zymoclean Gel DNA Recovery Kit (Zymo Research).  Two separate strategies were
employed to multimerize the ELF monomer and insert it into the pEC2-SC5 plasmid.  In
the first scheme, the ELF monomer was self-ligated with T4 DNA ligase in the supplied
ligase buffer at 0°C for <5 min before the ligation mixture was immediately loaded onto a
2 % agarose gel.  The 375-bp band, corresponding to and ELF pentamer (ELF5), was
excised from the gel, and the DNA was extracted with a QIAquick Kit.  The pEC2-SC5
plasmid was digested with Ban I (37°C, overnight) and dephosphorylated with calf
intestine phosphatase (CIP, NEB, room temperature, 5 min) before being purified on a 2
% agarose gel.  Linearized and dephosphorylated pEC2-SC5 was ligated for 3 h at room
temperature with the purified ELF pentamer fragment, and the ligation mixtures were
transformed into JM109 competent cells (Stratagene).  Transformation colonies were
test-digested with Xho I and Sal I; a band is expected at 468 bp if ELF pentamer
successfully inserted into pEC2-SC5.  A colony was isolated that carried the desired
plasmid, designated pEC2-SC5-ELF5.
In the second procedure attempted to produce pEC2-SC5-ELF5, the linearized and
dephosphorylated pEC2-SC5 plasmid was added directly to the ELF monomer ligation
mixture 30 s after ligation was initiated by the addition of T4 DNA ligase.  The ligation
was allowed to proceed for 3 h before transformation of the mixture into JM109
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competent cells.  A colony was isolated that harbored a plasmid designated
pEC2-SC5-ELF6; the multimer that had been inserted was the hexamer of ELF.
V.4 Results
Progress was made in the attempt to clone an artificial extracellular matrix protein
containing the RGD cell-binding domain from fibronectin and regular Phe residues for
incorporation of the analogue p-azidophenylalanine (RGD-F) along with negative control
proteins RDG-F and SC5-F.  The cloning strategy is depicted in Figure V-2.
A pET28cyl-phes* vector containing the A294G mutant phenylalanyl-tRNA
synthetase was created and confirmed through sequencing.  ELF monomer, isolated from
the digestion of pUC19-ELF, was successfully multimerized with T4 ligase (Figure V-5).
100 bp 
ladder
--100
--200
--300
--400
--500--600
--700
ELF multimerization
ELF pentamer --
(375 bp)
Figure V-5.  Representative 3% agaraose gel of a multimerization reaction.  ELF monomer
DNA (with Ban I sticky ends) was incubated with T4 DNA ligase at 0°C for 3 min before
being loaded onto the gel.
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Excising the 375-bp band from the agarose gel and ligating the
extracted DNA into a linearized pEC2-SC5 cloning vector resulted in a colony harboring
a pEC2-SC5-ELF5 (pentamer, Figure V-6).  In a separate experiment, ELF monomer was
multimerized in the presence of linearized pEC2-SC5 vector, followed by transformation
of the crude multimerization mixture.  This method produced a colony harboring pEC2-
SC5-ELF6 (hexamer, Figure V-6).
Pentamer DNA In situ100 bp 
ladder
100--
200--
300--
400--
500--
600--
700--
100 bp 
ladder
Figure V-6.  Test digestions (with Xho I and Sal I) of colonies of cells transformed with
ligation mixtures of pEC2-SC5/Ban I and ELF monomer with Ban I sticky ends.  Transformants
in lanes 2 to 9 resulted from ligations of pEC2-SC5/Ban I with ELF pentamer DNA that had
been excised from a 3% agarose gel of the ELF multimerization.  The circled band in lane 5
indicates presence of pEC2-SC5-ELF5 (pentamer).  Transformants in lanes 10 to 12 resulted
from in situ ligations of pEC2-SC5/Ban I with ELF monomer.  The circled band in lane 12
indicates the presence of pEC2-SC5-ELF6 (hexamer).
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V.5 Conclusions
The progress made in cloning the desired artificial extracellular matrix protein
constructs, especially in the difficult multimerization step, will facilitate future
production of these proteins.  The proteins, one containing the RGD cell-binding domain,
and negative control proteins for both the RGD and CS5 cell-binding domains, will
enable studies of cellular behavior on photocrosslinked substrates through the
incorporation of the photoreactive amino acid p-azidophenylalanine.
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A.1 pETcyl-phes* plasmid information
Submitted by: Stacey Maskarinec, Marissa Mock Date 4/22/04
Strain name: XL-1 blue (SupE44 hsdR17 recA1 endA1 gyrA46 thi relA1 lac-
F’[proAB+ lacIq lacZΔM15 Tn10(tetr)] (From Stratagene) ) / pET28cyl-phes*
Vector  (kb): pET28cyl-phes* (7.0)
Cloning  site: See plasmid map.
Construction of pET28cyl-phes* plasmid:
The phes* gene was cut from pUC19-FS (Nandita Sharma) with Sph I.  It was ligated
into the Sph I site of pET28cyl (Charles Liu).
Source available :
 12    % Glycerol culture in Marissa-3 freezer box
Culture conditions: 2xYT, 37°C
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A.1.1 Plasmid map
A.1.2 Position of elements
       bp
Vector size ................................................................................................................ 7003
Full insert region ................................................................................................ 532-2233
PheRS* gene...................................................................................................... 992-1073
pET28cyl-phes*
(7003 bp)
phes*
XhoI (167)
SphI (527)
XhoI (862)
SphI (2228)
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A.1.3 Full sequence (pET28cyl-phes*)
ATCCGGATATAGTTCCTCCTTTCAGCAAAAAACCCCTCAAGACCCGTTTAGAGGCCCCAAGGGGTTATGCTAGTTATT
GCTCAGCGGTGGCAGCAGCCAACTCAGCTTCCTTTCGGGCTTTGTTAGCAGCCGGATCTCAGTGGTGGTGGTGGTGGT
GCTCGA ctt act cga gaa gct t CAT GTG GTG GTG GTG GTG GTG ACC CAT TTG CTG TCC
ACC AGT CAT GCT CGC CAT gGTATATCTCCTTCTTAAAGTTAAACAAAATTATTTCTAGAGGGGAATTGTTAT
CCGCTCACAATTCCCCTATAGTGAGTCGTATTAATTTCGCGGGATCGAGATCTCGATCCTCTACGCCGGACGCATCGT
GGCCGGCATCACCGGCGCCACAGGTGCGGTTGCTGGCGCCTATATCGCCGACATCACCGATGGGGAAGATCGGGCTCG
CCACTTCGGGCTCATGAGCGCTTGTTTCGGCGTGGGTATGGTGGCAGGCCCCGTGGCCGGGGGACTGTTGGGCGCCAT
CTCCTTGCATGccgaacgaccgagcgcagcgagtcagtgagcgaggaagcggaagagcgcccaatacgcaaaccgcct
ctccccgcgcgttggccgattcattaatgcagctggcacgacaggtttcccgactggaaagcgggcagtgagcgcaac
gcaattaatgtgagttagctcactcattaggcaccccaggctttacactttatgcttccggctcgtatgttgtgtgga
attgtgagcggataacaatttcacacaggaaacagctatgaccatgattacgccaagctcgaaattaaccctcactaa
agggaacaaaagctggtaccgggccccccctcgaggtcgacggtatcgataagcttgatatcgaattcccccgggacc
aaaatggcaagtaaaatagcctgatgggataggctctaagtccaacgaaccagtgtcaccactg
TAGGCCTATATCAAGGAGGAAAGTCGTTTTTTGGGGAGTTCTGGGCAAATCTCCGGGGTTCCCCAATACGATCAATAA
CGAGTCGCCACCGTCGTCGGTTGAGTCGAAGGAAAGCCCGAAACAATCGTCGGCCTAGAGTCACCACCACCACCACCA
CGAGCT gaa tga gct ctt cga a GTA CAC CAC CAC CAC CAC CAC TGG GTA AAC GAC AGG
TGG TCA GTA CGA GCG GTA cCATATAGAGGAAGAATTTCAATTTGTTTTAATAAAGATCTCCCCTTAACAATA
GGCGAGTGTTAAGGGGATATCACTCAGCATAATTAAAGCGCCCTAGCTCTAGAGCTAGGAGATGCGGCCTGCGTAGCA
CCGGCCGTAGTGGCCGCGGTGTCCACGCCAACGACCGCGGATATAGCGGCTGTAGTGGCTACCCCTTCTAGCCCGAGC
GGTGAAGCCCGAGTACTCGCGAACAAAGCCGCACCCATACCACCGTCCGGGGCACCGGCCCCCTGACAACCCGCGGTA
GAGGAACGTACggcttgctggctcgcgtcgctcagtcactcgctccttcgccttctcgcgggttatgcgtttggcgga
gaggggcgcgcaaccggctaagtaattacgtcgaccgtgctgtccaaagggctgacctttcgcccgtcactcgcgttg
cgttaattacactcaatcgagtgagtaatccgtggggtccgaaatgtgaaatacgaaggccgagcatacaacacacct
taacactcgcctattgttaaagtgtgtcctttgtcgatactggtactaatgcggttcgagctttaattgggagtgatt
tcccttgttttcgaccatggcccgggggggagctccagctgccatagctattcgaactatagcttaagggggccctgg
ttttaccgttcattttatcggactaccctatccgagattcaggttgcttggtcacagtggtgac
XhoI (167)
SphI (527)
XhoI (862)
1
79
157
215
287
365
443
521
599
677
755
833
911
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acacaatgaggaaaaccatgtcacatctcgcagaactggttgccagtgcgaaggcggccattagccaggcgtcagat
gttgccgcgttagataatgtgcgcgtcgaatatttgggtaaaaaagggcacttaacccttcagatgacgaccctgcg
tgagctgccgccagaagagcgtccggcagctggtgcggttatcaacgaagcgaaagagcaggttcagcaggcgctga
atgcgcgtaaagcggaactggaaagcgctgcactgaatgcgcgtctggcggcggaaacgattgatgtctctctgcca
ggtcgtcgcattgaaaacggcggtctgcatccggttacccgtaccatcgaccgtatcgaaagtttcttcggtgagct
tggctttaccgtggcaaccgggccggaaatcgaagacgattatcataacttcgatgctctgaacattcctggtcacc
acccggcgcgcgctgaccacgacactttctggtttgacactacccgcctgctgcgtacccagacctctggcgtacag
atccgcaccatgaaagcccagcagccaccgattcgtatcatcgcgcctggccgtgtttatcgtaacgactacgacca
gactcacacgccgatgttccatcagatggaaggtctgattgttgataccaacatcagctttaccaacctgaaaggca
cgctgcacgacttcctgcgtaacttctttgaggaagatttgcagattcgcttccgtccttcctacttcccgtttacc
gaaccttctgcagaagtggacgtcatgggtaaaaacggtaaatggctggaagtgctgggctgcgggatggtgcatcc
gaacgtgttgcgtaacgttggcatcgacccggaagtttactctggtttcggcttcgggatggggatggagcgtctga
ctatgttgcgttacggcgtcaccgacctgcgttcattcttcgaaaacgatctgcgtttcctcaaacagtttaaataa
ggcaggaatagattatgaaattcagtgaactgtggttacgcgaatgggtgaacccggcgattgatagcgatgcgctg
tgtgttactccttttggtacagtgtagagcgtcttgaccaacggtcacgcttccgccggtaatcggtccgcagtcta
caacggcgcaatctattacacgcgcagcttataaacccattttttcccgtgaattgggaagtctactgctgggacgc
actcgacggcggtcttctcgcaggccgtcgaccacgccaatagttgcttcgctttctcgtccaagtcgtccgcgact
tacgcgcatttcgccttgacctttcgcgacgtgacttacgcgcagaccgccgcctttgctaactacagagagacggt
ccagcagcgtaacttttgccgccagacgtaggccaatgggcatggtagctggcatagctttcaaagaagccactcga
accgaaatggcaccgttggcccggcctttagcttctgctaatagtattgaagctacgagacttgtaaggaccagtgg
tgggccgcgcgcgactggtgctgtgaaagaccaaactgtgatgggcggacgacgcatgggtctggagaccgcatgtc
taggcgtggtactttcgggtcgtcggtggctaagcatagtagcgcggaccggcacaaatagcattgctgatgctggt
ctgagtgtgcggctacaaggtagtctaccttccagactaacaactatggttgtagtcgaaatggttggactttccgt
gcgacgtgctgaaggacgcattgaagaaactccttctaaacgtctaagcgaaggcaggaaggatgaagggcaaatgg
cttggaagacgtcttcacctgcagtacccatttttgccatttaccgaccttcacgacccgacgccctaccacgtagg
cttgcacaacgcattgcaaccgtagctgggccttcaaatgagaccaaagccgaagccctacccctacctcgcagact
gatacaacgcaatgccgcagtggctggacgcaagtaagaagcttttgctagacgcaaaggagtttgtcaaatttatt
ccgtccttatctaatactttaagtcacttgacaccaatgcgcttacccacttgggccgctaactatcgctacgcgac
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149
175
200
226
252
277
303
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ggcaggaatagattatgaaattcagtgaactgtggttacgcgaatgggtgaacccggcgattgatagcgatgcgctg
gcaaatcaaatcactatggcgggcctggaagttgggggatccactagttctagagcggccgccaccgcggtggagct
ccaattcgccctatagtgagtcgtattacaattcactggccgtcgttttacaacgtcgtgactgggaaaaccctggc
gttacccaacttaatcgccttgcatgCACCATTCCTTGCGGCGGCGGTGCTCAACGGCCTCAACCTACTACTGGGCT
GCTTCCTAATGCAGGAGTCGCATAAGGGAGAGCGTCGAGATCCCGGACACCATCGAATGGCGCAAAACCTTTCGCGG
TATGGCATGATAGCGCCCGGAAGAGAGTCAATTCAGGGTGGTGAATGTGAAACCAGTAACGTTATACGATGTCGCAG
AGTATGCCGGTGTCTCTTATCAGACCGTTTCCCGCGTGGTGAACCAGGCCAGCCACGTTTCTGCGAAAACGCGGGAA
AAAGTGGAAGCGGCGATGGCGGAGCTGAATTACATTCCCAACCGCGTGGCACAACAACTGGCGGGCAAACAGTCGTT
GCTGATTGGCGTTGCCACCTCCAGTCTGGCCCTGCACGCGCCGTCGCAAATTGTCGCGGCGATTAAATCTCGCGCCG
ATCAACTGGGTGCCAGCGTGGTGGTGTCGATGGTAGAACGAAGCGGCGTCGAAGCCTGTAAAGCGGCGGTGCACAAT
CTTCTCGCGCAACGCGTCAGTGGGCTGATCATTAACTATCCGCTGGATGACCAGGATGCCATTGCTGTGGAAGCTGC
CTGCACTAATGTTCCGGCGTTATTTCTTGATGTCTCTGACCAGACACCCATCAACAGTATTATTTTCTCCCATGAAG
ACGGTACGCGACTGGGCGTGGAGCATCTGGTCGCATTGGGTCACCAGCAAATCGCGCTGTTAGCGGGCCCATTAAGT
TCTGTCTCGGCGCGTCTGCGTCTGGCTGGCTGGCATAAATATCTCACTCGCAATCAAATTCAGCCGATAGCGGAACG
GGAAGGCGACTGGAGTGCCATGTCCGGTTTTCAACAAACCATGCAAATGCTGAATGAGGGCATCGTTCCCACTGCGA
TGCTGGTTGCCAACGATCAGATGGCGCTGGGCGCAATGCGCGCCATTACCGAGTCCGGGCTGCGCGTTGGTGCGGAT
ATCTCGGTAGTGGGATACGACGATACCGAAGACAGCTCATGTTATATCCCGCCGTTAACCACCATCAAACAGGATTT
TCGCCTGCTGGGGCAAACCAGCGTGGACCGCTTGCTGCAACTCTCTCAGGGCCAGGCGGTGAAGGGCAATCAGCTGT
TGCCCGTCTCACTGGTGAAAAGAAAAACCACCCTGGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGAT
TCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTAAGTTAGC
TCACTCATTAGGCACCGGGATCTCGACCGATGCCCTTGAGAGCCTTCAACCCAGTCAGCTCCTTCCGGTGGGCGCGG
GGCATGACTATCGTCGCCGCACTTATGACTGTCTTCTTTATCATGCAACTCGTAGGACAGGTGCCGGCAGCGCTCTG
GGTCATTTTCGGCGAGGACCGCTTTCGCTGGAGCGCGACGATGATCGGCCTGTCGCTTGCGGTATTCGGAATCTTGC
ACGCCCTCGCTCAAGCCTTCGTCACTGGTCCCGCCACCAAACGTTTCGGCGAGAAGCAGGCCATTATCGCCGGCATG
GCGGCCCCACGGGTGCGCATGATCGTGCTCCTGTCGTTGAGGACCCGGCTAGGCTGGCGGGGTTGCCTTACTGGTTA
GCAGAATGAATCACCGATACGCGAGCGAACGTGAAGCGACTGCTGCTGCAAAACGTCTGCGACCTGAGCAACAACAT
GAATGGTCTTCGGTTTCCGTGTTTCGTAAAGTCTGGAAACGCGGAAGTCAGCGCCCTGCACCATTATGTTCCGGATC
ccgtccttatctaatactttaagtcacttgacaccaatgcgcttacccacttgggccgctaactatcgctacgcgac
cgtttagtttagtgataccgcccggaccttcaaccccctaggtgatcaagatctcgccggcggtggcgccacctcga
ggttaagcgggatatcactcagcataatgttaagtgaccggcagcaaaatgttgcagcactgacccttttgggaccg
caatgggttgaattagcggaacgtacGTGGTAAGGAACGCCGCCGCCACGAGTTGCCGGAGTTGGATGATGACCCGA
CGAAGGATTACGTCCTCAGCGTATTCCCTCTCGCAGCTCTAGGGCCTGTGGTAGCTTACCGCGTTTTGGAAAGCGCC
ATACCGTACTATCGCGGGCCTTCTCTCAGTTAAGTCCCACCACTTACACTTTGGTCATTGCAATATGCTACAGCGTC
TCATACGGCCACAGAGAATAGTCTGGCAAAGGGCGCACCACTTGGTCCGGTCGGTGCAAAGACGCTTTTGCGCCCTT
TTTCACCTTCGCCGCTACCGCCTCGACTTAATGTAAGGGTTGGCGCACCGTGTTGTTGACCGCCCGTTTGTCAGCAA
CGACTAACCGCAACGGTGGAGGTCAGACCGGGACGTGCGCGGCAGCGTTTAACAGCGCCGCTAATTTAGAGCGCGGC
TAGTTGACCCACGGTCGCACCACCACAGCTACCATCTTGCTTCGCCGCAGCTTCGGACATTTCGCCGCCACGTGTTA
GAAGAGCGCGTTGCGCAGTCACCCGACTAGTAATTGATAGGCGACCTACTGGTCCTACGGTAACGACACCTTCGACG
GACGTGATTACAAGGCCGCAATAAAGAACTACAGAGACTGGTCTGTGGGTAGTTGTCATAATAAAAGAGGGTACTTC
TGCCATGCGCTGACCCGCACCTCGTAGACCAGCGTAACCCAGTGGTCGTTTAGCGCGACAATCGCCCGGGTAATTCA
AGACAGAGCCGCGCAGACGCAGACCGACCGACCGTATTTATAGAGTGAGCGTTAGTTTAAGTCGGCTATCGCCTTGC
CCTTCCGCTGACCTCACGGTACAGGCCAAAAGTTGTTTGGTACGTTTACGACTTACTCCCGTAGCAAGGGTGACGCT
ACGACCAACGGTTGCTAGTCTACCGCGACCCGCGTTACGCGCGGTAATGGCTCAGGCCCGACGCGCAACCACGCCTA
TAGAGCCATCACCCTATGCTGCTATGGCTTCTGTCGAGTACAATATAGGGCGGCAATTGGTGGTAGTTTGTCCTAAA
AGCGGACGACCCCGTTTGGTCGCACCTGGCGAACGACGTTGAGAGAGTCCCGGTCCGCCACTTCCCGTTAGTCGACA
ACGGGCAGAGTGACCACTTTTCTTTTTGGTGGGACCGCGGGTTATGCGTTTGGCGGAGAGGGGCGCGCAACCGGCTA
AGTAATTACGTCGACCGTGCTGTCCAAAGGGCTGACCTTTCGCCCGTCACTCGCGTTGCGTTAATTACATTCAATCG
AGTGAGTAATCCGTGGCCCTAGAGCTGGCTACGGGAACTCTCGGAAGTTGGGTCAGTCGAGGAAGGCCACCCGCGCC
CCGTACTGATAGCAGCGGCGTGAATACTGACAGAAGAAATAGTACGTTGAGCATCCTGTCCACGGCCGTCGCGAGAC
CCAGTAAAAGCCGCTCCTGGCGAAAGCGACCTCGCGCTGCTACTAGCCGGACAGCGAACGCCATAAGCCTTAGAACG
TGCGGGAGCGAGTTCGGAAGCAGTGACCAGGGCGGTGGTTTGCAAAGCCGCTCTTCGTCCGGTAATAGCGGCCGTAC
CGCCGGGGTGCCCACGCGTACTAGCACGAGGACAGCAACTCCTGGGCCGATCCGACCGCCCCAACGGAATGACCAAT
CGTCTTACTTAGTGGCTATGCGCTCGCTTGCACTTCGCTGACGACGACGTTTTGCAGACGCTGGACTCGTTGTTGTA
CTTACCAGAAGCCAAAGGCACAAAGCATTTCAGACCTTTGCGCCTTCAGTCGCGGGACGTGGTAATACAAGGCCTAG
SphI (2228)
1976
2053
2130
2207
2284
2361
2438
2515
2592
2669
2746
2823
2900
2977
3054
3131
3208
3285
3362
3439
3516
3593
3670
3747
3824
3901
3978
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TGCATCGCAGGATGCTGCTGGCTACCCTGTGGAACACCTACATCTGTATTAACGAAGCGCTGGCATTGACCCTGAGT
GATTTTTCTCTGGTCCCGCCGCATCCATACCGCCAGTTGTTTACCCTCACAACGTTCCAGTAACCGGGCATGTTCAT
CATCAGTAACCCGTATCGTGAGCATCCTCTCTCGTTTCATCGGTATCATTACCCCCATGAACAGAAATCCCCCTTAC
ACGGAGGCATCAGTGACCAAACAGGAAAAAACCGCCCTTAACATGGCCCGCTTTATCAGAAGCCAGACATTAACGCT
TCTGGAGAAACTCAACGAGCTGGACGCGGATGAACAGGCAGACATCTGTGAATCGCTTCACGACCACGCTGATGAGC
TTTACCGCAGCTGCCTCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGCAGCTCCCGGAGACGGTCACA
GCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTTGGCGGGTGTCGGGGCGC
AGCCATGACCCAGTCACGTAGCGATAGCGGAGTGTATACTGGCTTAACTATGCGGCATCAGAGCAGATTGTACTGAG
AGTGCACCATATATGCGGTGTGAAATACCGCACAGATGCGTAAGGAGAAAATACCGCATCAGGCGCTCTTCCGCTTC
CTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGT
TATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAG
GCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTG
GCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCC
TGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTAT
CTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTT
ATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGA
TTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACA
GTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAAC
CACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTT
TGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAACAATAAAACT
GTCTGCTTACATAAACAGTAATACAAGGGGTGTTATGAGCCATATTCAACGGGAAACGTCTTGCTCTAGGCCGCGAT
TAAATTCCAACATGGATGCTGATTTATATGGGTATAAATGGGCTCGCGATAATGTCGGGCAATCAGGTGCGACAATC
TATCGATTGTATGGGAAGCCCGATGCGCCAGAGTTGTTTCTGAAACATGGCAAAGGTAGCGTTGCCAATGATGTTAC
AGATGAGATGGTCAGACTAAACTGGCTGACGGAATTTATGCCTCTTCCGACCATCAAGCATTTTATCCGTACTCCTG
ATGATGCATGGTTACTCACCACTGCGATCCCCGGGAAAACAGCATTCCAGGTATTAGAAGAATATCCTGATTCAGGT
GAAAATATTGTTGATGCGCTGGCAGTGTTCCTGCGCCGGTTGCATTCGATTCCTGTTTGTAATTGTCCTTTTAACAG
CGATCGCGTATTTCGTCTCGCTCAGGCGCAATCACGAATGAATAACGGTTTGGTTGATGCGAGTGATTTTGATGACG
ACGTAGCGTCCTACGACGACCGATGGGACACCTTGTGGATGTAGACATAATTGCTTCGCGACCGTAACTGGGACTCA
CTAAAAAGAGACCAGGGCGGCGTAGGTATGGCGGTCAACAAATGGGAGTGTTGCAAGGTCATTGGCCCGTACAAGTA
GTAGTCATTGGGCATAGCACTCGTAGGAGAGAGCAAAGTAGCCATAGTAATGGGGGTACTTGTCTTTAGGGGGAATG
TGCCTCCGTAGTCACTGGTTTGTCCTTTTTTGGCGGGAATTGTACCGGGCGAAATAGTCTTCGGTCTGTAATTGCGA
AGACCTCTTTGAGTTGCTCGACCTGCGCCTACTTGTCCGTCTGTAGACACTTAGCGAAGTGCTGGTGCGACTACTCG
AAATGGCGTCGACGGAGCGCGCAAAGCCACTACTGCCACTTTTGGAGACTGTGTACGTCGAGGGCCTCTGCCAGTGT
CGAACAGACATTCGCCTACGGCCCTCGTCTGTTCGGGCAGTCCCGCGCAGTCGCCCACAACCGCCCACAGCCCCGCG
TCGGTACTGGGTCAGTGCATCGCTATCGCCTCACATATGACCGAATTGATACGCCGTAGTCTCGTCTAACATGACTC
TCACGTGGTATATACGCCACACTTTATGGCGTGTCTACGCATTCCTCTTTTATGGCGTAGTCCGCGAGAAGGCGAAG
GAGCGAGTGACTGAGCGACGCGAGCCAGCAAGCCGACGCCGCTCGCCATAGTCGAGTGAGTTTCCGCCATTATGCCA
ATAGGTGTCTTAGTCCCCTATTGCGTCCTTTCTTGTACACTCGTTTTCCGGTCGTTTTCCGGTCCTTGGCATTTTTC
CGGCGCAACGACCGCAAAAAGGTATCCGAGGCGGGGGGACTGCTCGTAGTGTTTTTAGCTGCGAGTTCAGTCTCCAC
CGCTTTGGGCTGTCCTGATATTTCTATGGTCCGCAAAGGGGGACCTTCGAGGGAGCACGCGAGAGGACAAGGCTGGG
ACGGCGAATGGCCTATGGACAGGCGGAAAGAGGGAAGCCCTTCGCACCGCGAAAGAGTATCGAGTGCGACATCCATA
GAGTCAAGCCACATCCAGCAAGCGAGGTTCGACCCGACACACGTGCTTGGGGGGCAAGTCGGGCTGGCGACGCGGAA
TAGGCCATTGATAGCAGAACTCAGGTTGGGCCATTCTGTGCTGAATAGCGGTGACCGTCGTCGGTGACCATTGTCCT
AATCGTCTCGCTCCATACATCCGCCACGATGTCTCAAGAACTTCACCACCGGATTGATGCCGATGTGATCTTCCTGT
CATAAACCATAGACGCGAGACGACTTCGGTCAATGGAAGCCTTTTTCTCAACCATCGAGAACTAGGCCGTTTGTTTG
GTGGCGACCATCGCCACCAAAAAAACAAACGTTCGTCGTCTAATGCGCGTCTTTTTTTCCTAGAGTTCTTCTAGGAA
ACTAGAAAAGATGCCCCAGACTGCGAGTCACCTTGCTTTTGAGTGCAATTCCCTAAAACCAGTACTTGTTATTTTGA
CAGACGAATGTATTTGTCATTATGTTCCCCACAATACTCGGTATAAGTTGCCCTTTGCAGAACGAGATCCGGCGCTA
ATTTAAGGTTGTACCTACGACTAAATATACCCATATTTACCCGAGCGCTATTACAGCCCGTTAGTCCACGCTGTTAG
ATAGCTAACATACCCTTCGGGCTACGCGGTCTCAACAAAGACTTTGTACCGTTTCCATCGCAACGGTTACTACAATG
TCTACTCTACCAGTCTGATTTGACCGACTGCCTTAAATACGGAGAAGGCTGGTAGTTCGTAAAATAGGCATGAGGAC
TACTACGTACCAATGAGTGGTGACGCTAGGGGCCCTTTTGTCGTAAGGTCCATAATCTTCTTATAGGACTAAGTCCA
CTTTTATAACAACTACGCGACCGTCACAAGGACGCGGCCAACGTAAGCTAAGGACAAACATTAACAGGAAAATTGTC
GCTAGCGCATAAAGCAGAGCGAGTCCGCGTTAGTGCTTACTTATTGCCAAACCAACTACGCTCACTAAAACTACTGC
4055
4132
4209
4286
4363
4440
4517
4594
4671
4748
4825
4902
4979
5056
5133
5210
5287
5364
5441
5518
5595
5672
5749
5826
5903
5980
6057
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AGCGTAATGGCTGGCCTGTTGAACAAGTCTGGAAAGAAATGCATAAACTTTTGCCATTCTCACCGGATTCAGTCGTC
ACTCATGGTGATTTCTCACTTGATAACCTTATTTTTGACGAGGGGAAATTAATAGGTTGTATTGATGTTGGACGAGT
CGGAATCGCAGACCGATACCAGGATCTTGCCATCCTATGGAACTGCCTCGGTGAGTTTTCTCCTTCATTACAGAAAC
GGCTTTTTCAAAAATATGGTATTGATAATCCTGATATGAATAAATTGCAGTTTCATTTGATGCTCGATGAGTTTTTC
TAAGAATTAATTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTC
CCCGAAAAGTGCCACCTGAAATTGTAAACGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCA
TTTTTTAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGGGTTGAGTGTTGT
TCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGGACTCCAACGTCAAAGGGCGAAAAACCGTCTATCAGGGCG
ATGGCCCACTACGTGAACCATCACCCTAATCAAGTTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCT
AAAGGGAGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCGAAAGG
AGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCACACCCGCCGCGCTTAATGCGCCGC
TACAGGGCGCGTCCCATTCGCCA
TCGCATTACCGACCGGACAACTTGTTCAGACCTTTCTTTACGTATTTGAAAACGGTAAGAGTGGCCTAAGTCAGCAG
TGAGTACCACTAAAGAGTGAACTATTGGAATAAAAACTGCTCCCCTTTAATTATCCAACATAACTACAACCTGCTCA
GCCTTAGCGTCTGGCTATGGTCCTAGAACGGTAGGATACCTTGACGGAGCCACTCAAAAGAGGAAGTAATGTCTTTG
CCGAAAAAGTTTTTATACCATAACTATTAGGACTATACTTATTTAACGTCAAAGTAAACTACGAGCTACTCAAAAAG
ATTCTTAATTAAGTACTCGCCTATGTATAAACTTACATAAATCTTTTTATTTGTTTATCCCCAAGGCGCGTGTAAAG
GGGCTTTTCACGGTGGACTTTAACATTTGCAATTATAAAACAATTTTAAGCGCAATTTAAAAACAATTTAGTCGAGT
AAAAAATTGGTTATCCGGCTTTAGCCGTTTTAGGGAATATTTAGTTTTCTTATCTGGCTCTATCCCAACTCACAACA
AGGTCAAACCTTGTTCTCAGGTGATAATTTCTTGCACCTGAGGTTGCAGTTTCCCGCTTTTTGGCAGATAGTCCCGC
TACCGGGTGATGCACTTGGTAGTGGGATTAGTTCAAAAAACCCCAGCTCCACGGCATTTCGTGATTTAGCCTTGGGA
TTTCCCTCGGGGGCTAAATCTCGAACTGCCCCTTTCGGCCGCTTGCACCGCTCTTTCCTTCCCTTCTTTCGCTTTCC
TCGCCCGCGATCCCGCGACCGTTCACATCGCCAGTGCGACGCGCATTGGTGGTGTGGGCGGCGCGAATTACGCGGCG
ATGTCCCGCGCAGGGTAAGCGGT
6134
6211
6288
6365
6442
6519
6596
6673
6750
6827
6904
6981
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A.2 pEC2-SC5, -RGD, -RDG plasmid information
Submitted by Marissa Mock Date 4/22/04
Strain name/ XL-1 blue (SupE44 hsdR17 recA1 endA1 gyrA46 thi relA1 lac-
F’[proAB+ lacIq lacZΔM15 Tn10(tetr)] (From Stratagene) )/ pEC2-SC5
pEC2-RGD
pEC2-RDG
Vector  (kb) :  pEC2-SC5
pEC2-RGD
pEC2-RDG
Cloning  site: See plasmid map.
Construction of pEC2-CBD plasmids
The cell binding domain region was cut out of the appropriate pUC19-SC5, pUC19-
RGD, or pUC19-RDG vector with EcoR I/ BamH I digestion.  The pEC2 (Eric Cantor)
vector was cut with EcoR I/BamH I and ligated with the inserts to produce pEC2-SC5,
pEC2-RGD, and pEC2-RDG.
Plasmid map and full sequence are shown only for pEC2-SC5; others are similar.
Source available :
12    % Glycerol culture in Marissa freezer box
Culture conditions: 2xYT, 37°C
A-10
A.2.1 Plasmid map
A.2.2 Position of elements
      bp
Vector size ................................................................................................................ 4110
SC5 insert ............................................................................................................ 314-420
RGD insert........................................................................................................... 314-414
RDG insert .......................................................................................................... 314-414
pEC2-SC5
(4110 bp)
EcoRI
BanI
BamHI
A-11
A.2.3 Full sequence (pEC2-SC5)
GTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAA
AGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACT
TCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGG
GAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAgatctgatcag aat tcg tcg
acg cta gct tcc tcg atg gtg aag aga tcc aga tcg gcc aca tcc cgc gtg aag ttg atg
att acc acc tgt acg cta gcg cgg tgc cgc tcg agg gatccatctagagtcgacgtcggccgttaaccta
ggagatctgcaGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAAT
AGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCT
GGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACA
CGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCgtgcCTCACTGATTAAGCATTGGT
AACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGAT
CCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCTTAATAAGATGATCT
TCTTGAGATCGTTTTGGTCTGCGCGTAATCTCTTGCTCTGAAAACGAAAAAACCGCCTTGCAGGGCGGTTTTTCGAAGGTTC
TCTGAGCTACCAACTCTTTGAACCGAGGTAACTGGCTTGGAGGAGCGCAGTCACCAAAACTTGTCCTTTCAGTTTAGCCTTA
ACCGGCGCATGACTTCAAGACTAACTCCTCTAAATCAATTACCAGTGGCTGCTGCCAGTGGTGCTTTTGCATGTCTTTCCGG
GTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGACTGAACGGGGGGTTCGTGCATACAGTCCAGCTTGGAG
CGAACTGCCTACCCGGAACTGAGTGTCAGGCGTGGAATGAGACAAACGCGGCCATAACAGCGGAATGACACCGGTAAACCGA
CAACTGCGGCCCGTTCTCGTTGAGCCAGCGGCGTATGTGATAAGAGTCTTACTGAACCAACTCATGAGTGGTCAGTGTCTTT
TCGTAGAATGCCTACCGTACTGTCATTCTCTTAATACGTCACGACGGTATTGGTACTCACTATTGTGACGCCGGTTGAATGA
AGACTGTTGCTAGCCTCCTGGCTTCCTCGATTGGCGAAAAAACGTGTTGTACCCCCTAGTACATTGAGCGGAACTAGCAACC
CTTGGCCTCGACTTACTTCGGTATGGTTTGCTGCTCGCACTGTGGTGCTACGGACGTctagactagtc tta agc agc
tgc gat cga agg agc tac cac ttc tct agg tct agc cgg tgt agg gcg cac ttc aac tac
taa tgg tgg aca tgc gat cgc gcc acg gcg agc tcc ctaggtagatctcagctgcagccggcaattggat
cctctagacgtCGTTACCGTTGTTGCAACGCGTTTGATAATTGACCGCTTGATGAATGAGATCGAAGGGCCGTTGTTAATTA
TCTGACCTACCTCCGCCTATTTCAACGTCCTGGTGAAGACGCGAGCCGGGAAGGCCGACCGACCAAATAACGACTATTTAGA
CCTCGGCCACTCGCACCCAGAGCGCCATAGTAACGTCGTGACCCCGGTCTACCATTCGGGAGGGCATAGCATCAATAGATGT
GCTGCCCCTCAGTCCGTTGATACCTACTTGCTTTATCTGTCTAGCGACTCTATCCACGcacgGAGTGACTAATTCGTAACCA
TTGACAGTCTGGTTCAAATGAGTATATATGAAATCTAACTAAATTTTGAAGTAAAAATTAAATTTTCCTAGATCCACTTCTA
GGAAAAACTATTAGAGTACTGGTTTTAGGGAATTGCACTCAAAAGCAAGGTGACTCGCAGTCTGGGGAATTATTCTACTAGA
AGAACTCTAGCAAAACCAGACGCGCATTAGAGAACGAGACTTTTGCTTTTTTGGCGGAACGTCCCGCCAAAAAGCTTCCAAG
AGACTCGATGGTTGAGAAACTTGGCTCCATTGACCGAACCTCCTCGCGTCAGTGGTTTTGAACAGGAAAGTCAAATCGGAAT
TGGCCGCGTACTGAAGTTCTGATTGAGGAGATTTAGTTAATGGTCACCGACGACGGTCACCACGAAAACGTACAGAAAGGCC
CAACCTGAGTTCTGCTATCAATGGCCTATTCCGCGTCGCCAGCCTGACTTGCCCCCCAAGCACGTATGTCAGGTCGAACCTC
GCTTGACGGATGGGCCTTGACTCACAGTCCGCACCTTACTCTGTTTGCGCCGGTATTGTCGCCTTACTGTGGCCATTTGGCT
 L   D  G  E   E   I   Q  I   G  H  I   P   R   E   V  D  
D  Y   H  L   Y  
PstI EcoRI
NheI
NheI BanI XhoI BamHI
PstI
1
83
165
247
324
384
454
536
618
700
782
864
946
1028
1110
1192
1274
1
17
A-12
AAGGCAGGAACAGGAGAGCGCACGAGGGAGCCGCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACC
ACTGATTTGAGCGTCAGATTTCGTGATGCTTGTCAGGGGGGCGGAGCCTATGGAAAAACGGCTTTGCCGCGGCCCTCTCACT
TCCCTGTTAAGTATCTTCCTGGCATCTTCCAGGAAATCTCCGCCCCGTTCGTAAGCCATTTCCGCTCGCCGCAGTCGAACGA
CCGAGCGTAGCGAGTCAGTGAGCGAGGAAGCGGAATATATCCTGTATCACATATTCTGCTGACGCACCGGTGCAGCCTTTTT
TCTCCTGCCACATGAAGCACTTCACTGACACCCTCATCAGTGCCAACATAGTAAGCCAGTATACACTCCGCTAGCGCTGAGG
TCTGCCTCGTGAAGAAGGTGTTGCTGACTCATACCAGGCCTGAATCGCCCCATCATCCAGCCAGAAAGTGAGGGAGCCACGG
TTGATGAGAGCTTTGTTGTAGGTGGACCAGTTGGTGATTTTGAACTTTTGCTTTGCCACGGAACGGTCTGCGTTGTCGGGAA
GATGCGTGATCTGATCCTTCAACTCAGCAAAAGTTCGATTTATTCAACAAAGCCACGTTGTGTCTCAAAATCTCTGATGTTA
CATTGCACAAGATAAAAATATATCATCATGAACAATAAAACTGTCTGCTTACATAAACAGTAATACAAGGGGTGTTATGAGC
CATATTCAACGGGAAACGTCTTGCTCGAGGCCGCGATTAAATTCCAACATGGATGCTGATTTATATGGGTATAAATGGGCTC
GCGATAATGTCGGGCAATCAGGTGCGACAATCTATCGATTGTATGGGAAGCCCGATGCGCCAGAGTTGTTTCTGAAACATGG
CAAAGGTAGCGTTGCCAATGATGTTACAGATGAGATGGTCAGACTAAACTGGCTGACGGAATTTATGCCTCTTCCGACCATC
AAGCATTTTATCCGTACTCCTGATGATGCATGGTTACTCACCACTGCGATCCCCGGGAAAACAGCATTCCAGGTATTAGAAG
AATATCCTGATTCAGGTGAAAATATTGTTGATGCGCTGGCAGTGTTCCTGCGCCGGTTGCATTCGATTCCTGTTTGTAATTG
TCCTTTTAACAGCGATCGCGTATTTCGTCTCGCTCAGGCGCAATCACGAATGAATAACGGTTTGGTTGATGCGAGTGATTTT
GATGACGAGCGTAATGGCTGGCCTGTTGAACAAGTCTGGAAAGAAATGCATAAGCTTTTGCCATTCTCACCGGATTCAGTCG
TCACTCATGGTGATTTCTCACTTGATAACCTTATTTTTGACGAGGGGAAATTAATAGGTTGTATTGATGTTGGACGAGTCGG
AATCGCAGACCGATACCAGGATCTTGCCATCCTATGGAACTGCCTCGGTGAGTTTTCTCCTTCATTACAGAAACGGCTTTTT
CAAAAATATGGTATTGATAATCCTGATATGAATAAATTGCAGTTTCATTTGATGCTCGATGAGTTTTTCTAATCAGAATTGG
TTCCGTCCTTGTCCTCTCGCGTGCTCCCTCGGCGGTCCCCCTTTGCGGACCATAGAAATATCAGGACAGCCCAAAGCGGTGG
TGACTAAACTCGCAGTCTAAAGCACTACGAACAGTCCCCCCGCCTCGGATACCTTTTTGCCGAAACGGCGCCGGGAGAGTGA
AGGGACAATTCATAGAAGGACCGTAGAAGGTCCTTTAGAGGCGGGGCAAGCATTCGGTAAAGGCGAGCGGCGTCAGCTTGCT
GGCTCGCATCGCTCAGTCACTCGCTCCTTCGCCTTATATAGGACATAGTGTATAAGACGACTGCGTGGCCACGTCGGAAAAA
AGAGGACGGTGTACTTCGTGAAGTGACTGTGGGAGTAGTCACGGTTGTATCATTCGGTCATATGTGAGGCGATCGCGACTCC
AGACGGAGCACTTCTTCCACAACGACTGAGTATGGTCCGGACTTAGCGGGGTAGTAGGTCGGTCTTTCACTCCCTCGGTGCC
AACTACTCTCGAAACAACATCCACCTGGTCAACCACTAAAACTTGAAAACGAAACGGTGCCTTGCCAGACGCAACAGCCCTT
CTACGCACTAGACTAGGAAGTTGAGTCGTTTTCAAGCTAAATAAGTTGTTTCGGTGCAACACAGAGTTTTAGAGACTACAAT
GTAACGTGTTCTATTTTTATATAGTAGTACTTGTTATTTTGACAGACGAATGTATTTGTCATTATGTTCCCCACAATACTCG
GTATAAGTTGCCCTTTGCAGAACGAGCTCCGGCGCTAATTTAAGGTTGTACCTACGACTAAATATACCCATATTTACCCGAG
CGCTATTACAGCCCGTTAGTCCACGCTGTTAGATAGCTAACATACCCTTCGGGCTACGCGGTCTCAACAAAGACTTTGTACC
GTTTCCATCGCAACGGTTACTACAATGTCTACTCTACCAGTCTGATTTGACCGACTGCCTTAAATACGGAGAAGGCTGGTAG
TTCGTAAAATAGGCATGAGGACTACTACGTACCAATGAGTGGTGACGCTAGGGGCCCTTTTGTCGTAAGGTCCATAATCTTC
TTATAGGACTAAGTCCACTTTTATAACAACTACGCGACCGTCACAAGGACGCGGCCAACGTAAGCTAAGGACAAACATTAAC
AGGAAAATTGTCGCTAGCGCATAAAGCAGAGCGAGTCCGCGTTAGTGCTTACTTATTGCCAAACCAACTACGCTCACTAAAA
CTACTGCTCGCATTACCGACCGGACAACTTGTTCAGACCTTTCTTTACGTATTCGAAAACGGTAAGAGTGGCCTAAGTCAGC
AGTGAGTACCACTAAAGAGTGAACTATTGGAATAAAAACTGCTCCCCTTTAATTATCCAACATAACTACAACCTGCTCAGCC
TTAGCGTCTGGCTATGGTCCTAGAACGGTAGGATACCTTGACGGAGCCACTCAAAAGAGGAAGTAATGTCTTTGCCGAAAAA
GTTTTTATACCATAACTATTAGGACTATACTTATTTAACGTCAAAGTAAACTACGAGCTACTCAAAAAGATTAGTCTTAACC
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TTAATTGGTTGTAACACTGGCAGAGCATTACGCTGACTTGACGGGACGGCGGCTTTGTTGAATAAATCGAACTTTTGCTGAG
TTGAAGGATCAGATCACGCATCTTCCCGACAACGCAGACCGTTCCGTGGCAAAGCAAAAGTTCAAAATCACCAACTGGTCCA
CCTACAACAAAGCTCTCATCAACCGTGGCTCCCTCACTTTCTGGCTGGATGATGGGGCGATTCAGGCCTGGTATGAGTCAGC
AACACCTTCTTCACGAGGCAGACCTCAGCGCTCAAAGATGCAGGGGTAAAAGCTAACCGCATCTTTACCGACAAGGCATCCG
GCAGTTCAACAGATCGGGAAGGGCTGGATTTGCTGAGGATGAAGGTGGAGGAAGGTGATGTCATTCTGGTGAAGAAGCTCGA
CCGTCTTGGCCGCGACACCGCCGACATGATCCAACTGATAAAAGAGTTTGATGCTCAGGGTGTAGCGGTTCGGTTTATTGAC
GACGGGATCAGTACCGACGGTGATATGGGGCAAATGGTGGTCACCATCCTGTCGGCTGTGGCACAGGCTGAACGCCGGAGGA
TCgatcCTAGAGCGCACGAATGAGGGCCGACAGGAAGCAAAGCTGAAAGGAATCAAATTTGGCCGCAGGCGTACCGTGGACA
GGAACGTCGTGCTGACGCTTCATCAGAAGGGCACTGGTGCAACGGAAATTGCTCATCAGCTCAGTATTGCCCGCTCCACGGT
TTATAAAATTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGA
CGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCT
CATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTT
ATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGT
TGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCC
AATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGT
AATTAACCAACATTGTGACCGTCTCGTAATGCGACTGAACTGCCCTGCCGCCGAAACAACTTATTTAGCTTGAAAACGACTC
AACTTCCTAGTCTAGTGCGTAGAAGGGCTGTTGCGTCTGGCAAGGCACCGTTTCGTTTTCAAGTTTTAGTGGTTGACCAGGT
GGATGTTGTTTCGAGAGTAGTTGGCACCGAGGGAGTGAAAGACCGACCTACTACCCCGCTAAGTCCGGACCATACTCAGTCG
TTGTGGAAGAAGTGCTCCGTCTGGAGTCGCGAGTTTCTACGTCCCCATTTTCGATTGGCGTAGAAATGGCTGTTCCGTAGGC
CGTCAAGTTGTCTAGCCCTTCCCGACCTAAACGACTCCTACTTCCACCTCCTTCCACTACAGTAAGACCACTTCTTCGAGCT
GGCAGAACCGGCGCTGTGGCGGCTGTACTAGGTTGACTATTTTCTCAAACTACGAGTCCCACATCGCCAAGCCAAATAACTG
CTGCCCTAGTCATGGCTGCCACTATACCCCGTTTACCACCAGTGGTAGGACAGCCGACACCGTGTCCGACTTGCGGCCTCCT
AGctagGATCTCGCGTGCTTACTCCCGGCTGTCCTTCGTTTCGACTTTCCTTAGTTTAAACCGGCGTCCGCATGGCACCTGT
CCTTGCAGCACGACTGCGAAGTAGTCTTCCCGTGACCACGTTGCCTTTAACGAGTAGTCGAGTCATAACGGGCGAGGTGCCA
AATATTTTAAGAACTTCTGCTTTCCCGGAGCACTATGCGGATAAAAATATCCAATTACAGTACTATTATTACCAAAGAATCT
GCAGTCCACCGTGAAAAGCCCCTTTACACGCGCCTTGGGGATAAACAAATAAAAAGATTTATGTAAGTTTATACATAGGCGA
GTACTCTGTTATTGGGACTATTTACGAAGTTATTATAACTTTTTCCTTCTCATACTCATAAGTTGTAAAGGCACAGCGGGAA
TAAGGGAAAAAACGCCGTAAAACGGAAGGACAAAAACGAGTGGGTCTTTGCGACCACTTTCATTTTCTACGACTTCTAGTCA
ACCCACGTGCTCACCCAATGTAGCTTGACCTAGAGTTGTCGCCATTCTAGGAACTCTCAAAAGCGGGGCTTCTTGCAAAAGG
TTACTACTCGTGAAAATTTCAAGACGATACACCGCGCCATAATAGGGCA
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A.3 pEC2-SC5-ELF5 and -ELF6 information
Submitted by Marissa Mock Date 4/22/04
Strain name: JM109 (e14–(McrA–) recA1 endA1 gyrA96 thi-1 hsdR17 (rK–
mK+) supE44 relA1 £G(lac-proAB) [F´ traD36 proAB lacIqZ£GM15). (From Zymo
Research) )/ pEC2-SC5-ELF5
or  / pEC2-SC5-ELF6
Vector  (kb): pEC2-SC5-ELF5 (X)
pEC2-SC5-ELF6 (X)
Construction of pEC2-CBD plasmids
ELF monomer (see sequence below) was obtained through Ban I digestion of pUC19-
ELF (Nandita Sharma).
pEC2-SC5-ELF5:
The 75 bp fragment was multimerized through ligation with T4 DNA ligase for 3 minutes
at 0°C.  The ligation mixture was run on a 2% agarose gel, and the band corresponding to
pentamer (375 bp) was cut out and extracted from the gel.  The pentamer DNA was
ligated with pEC2-SC5 vector that had been digested with Ban I and dephosphorylated
with CIP, to yield pEC2-SC5-ELF5.
pEC2-SC5-ELF6:
The 75 bp ELF fragment was mixed with T4 ligase at 0°C for 30 s and added directly to
pEC2-SC5 vector that had been digested with Ban I and dephosphorylated with CIP.  The
entire ligation mixture was transformed in JM109 competent cells; screened colonies
revealed a strain containing pEC2-SC5-ELF6.
ELF monomer sequence:
ggtgccgggtgtgggcgttccgggcgtgggtgtaccgggcttcggtgtcccgggcgtaggtgttccgggtgtcggggtgcc
Plasmid map and full sequence shown only for pEC2-SC5-ELF5; other is similar.
Source available :
12    % Glycerol culture in Marissa freezer box
Culture conditions: 2xYT, 37°C                       
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A.3.1 Plasmid map
A.3.2 Position of elements
      bp
Vector size ................................................................................................................ 4485
SC5 cell binding domain ...................................................................................... 314-406
ELF pentamer ...................................................................................................... 407-782
pEC2-SC5-ELF5
(4485 bp)
EcoRI
SalI NheI
NheI
XhoI
BamHI
SalI
XhoI
A-16
A.3.3 Full sequence (pEC2-SC5-ELF5)
GTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACA
GAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCC
AACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGC
CTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAgatctgatc
ag aat tcg tcg acg cta gct tcc tcg atg gtg aag aga tcc aga tcg gcc aca tcc cgc
gtg aag ttg atg att acc acc tgt acg cta gcg cg gtgccgggtgtgggcgttccgggcgtgggtg
taccgggcttcggtgtcccgggcgtaggtgttccgggtgtcggggtgccgggtgtgggcgttccgggcgtgggtgtac
cgggcttcggtgtcccgggcgtaggtgttccgggtgtcggggtgccgggtgtgggcgttccgggcgtgggtgtaccgg
gcttcggtgtcccgggcgtaggtgttccgggtgtcggggtgccgggtgtgggcgttccgggcgtgggtgtaccgggct
tcggtgtcccgggcgtaggtgttccgggtgtcggggtgccgggtgtgggcgttccgggcgtgggtgtaccgggcttcg
gtgtcccgggcgtaggtgttccgggtgtcggg gtg ccg ctc gag g gatccatctagagtcgacgtcggccgt
taacctaggagatctgcaGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGG
CAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTT
ATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCC
CGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCg
CAACTGCGGCCCGTTCTCGTTGAGCCAGCGGCGTATGTGATAAGAGTCTTACTGAACCAACTCATGAGTGGTCAGTGT
CTTTTCGTAGAATGCCTACCGTACTGTCATTCTCTTAATACGTCACGACGGTATTGGTACTCACTATTGTGACGCCGG
TTGAATGAAGACTGTTGCTAGCCTCCTGGCTTCCTCGATTGGCGAAAAAACGTGTTGTACCCCCTAGTACATTGAGCG
GAACTAGCAACCCTTGGCCTCGACTTACTTCGGTATGGTTTGCTGCTCGCACTGTGGTGCTACGGACGTctagactag
tc tta agc agc tgc gat cga agg agc tac cac ttc tct agg tct agc cgg tgt agg gcg
cac ttc aac tac taa tgg tgg aca tgc gat cgc gc cacggcccacacccgcaaggcccgcacccac
atggcccgaagccacagggcccgcatccacaaggcccacagccccacggcccacacccgcaaggcccgcacccacatg
gcccgaagccacagggcccgcatccacaaggcccacagccccacggcccacacccgcaaggcccgcacccacatggcc
cgaagccacagggcccgcatccacaaggcccacagccccacggcccacacccgcaaggcccgcacccacatggcccga
agccacagggcccgcatccacaaggcccacagccccacggcccacacccgcaaggcccgcacccacatggcccgaagc
cacagggcccgcatccacaaggcccacagccc cac ggc gag ctc c ctaggtagatctcagctgcagccggca
attggatcctctagacgtCGTTACCGTTGTTGCAACGCGTTTGATAATTGACCGCTTGATGAATGAGATCGAAGGGCC
GTTGTTAATTATCTGACCTACCTCCGCCTATTTCAACGTCCTGGTGAAGACGCGAGCCGGGAAGGCCGACCGACCAAA
TAACGACTATTTAGACCTCGGCCACTCGCACCCAGAGCGCCATAGTAACGTCGTGACCCCGGTCTACCATTCGGGAGG
GCATAGCATCAATAGATGTGCTGCCCCTCAGTCCGTTGATACCTACTTGCTTTATCTGTCTAGCGACTCTATCCACGc
 L   D  G  E   E   I   Q  I   G  H  I   P   
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tgcCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTT
TTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCA
CTGAGCGTCAGACCCCTTAATAAGATGATCTTCTTGAGATCGTTTTGGTCTGCGCGTAATCTCTTGCTCTGAAAACGA
AAAAACCGCCTTGCAGGGCGGTTTTTCGAAGGTTCTCTGAGCTACCAACTCTTTGAACCGAGGTAACTGGCTTGGAGG
AGCGCAGTCACCAAAACTTGTCCTTTCAGTTTAGCCTTAACCGGCGCATGACTTCAAGACTAACTCCTCTAAATCAAT
TACCAGTGGCTGCTGCCAGTGGTGCTTTTGCATGTCTTTCCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGC
AGCGGTCGGACTGAACGGGGGGTTCGTGCATACAGTCCAGCTTGGAGCGAACTGCCTACCCGGAACTGAGTGTCAGGC
GTGGAATGAGACAAACGCGGCCATAACAGCGGAATGACACCGGTAAACCGAAAGGCAGGAACAGGAGAGCGCACGAGG
GAGCCGCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCACTGATTTGAGCGTCAGATTTCG
TGATGCTTGTCAGGGGGGCGGAGCCTATGGAAAAACGGCTTTGCCGCGGCCCTCTCACTTCCCTGTTAAGTATCTTCC
TGGCATCTTCCAGGAAATCTCCGCCCCGTTCGTAAGCCATTTCCGCTCGCCGCAGTCGAACGACCGAGCGTAGCGAGT
CAGTGAGCGAGGAAGCGGAATATATCCTGTATCACATATTCTGCTGACGCACCGGTGCAGCCTTTTTTCTCCTGCCAC
ATGAAGCACTTCACTGACACCCTCATCAGTGCCAACATAGTAAGCCAGTATACACTCCGCTAGCGCTGAGGTCTGCCT
CGTGAAGAAGGTGTTGCTGACTCATACCAGGCCTGAATCGCCCCATCATCCAGCCAGAAAGTGAGGGAGCCACGGTTG
ATGAGAGCTTTGTTGTAGGTGGACCAGTTGGTGATTTTGAACTTTTGCTTTGCCACGGAACGGTCTGCGTTGTCGGGA
AGATGCGTGATCTGATCCTTCAACTCAGCAAAAGTTCGATTTATTCAACAAAGCCACGTTGTGTCTCAAAATCTCTGA
TGTTACATTGCACAAGATAAAAATATATCATCATGAACAATAAAACTGTCTGCTTACATAAACAGTAATACAAGGGGT
GTTATGAGCCATATTCAACGGGAAACGTCTTGCTCGAGGCCGCGATTAAATTCCAACATGGATGCTGATTTATATGGG
TATAAATGGGCTCGCGATAATGTCGGGCAATCAGGTGCGACAATCTATCGATTGTATGGGAAGCCCGATGCGCCAGAG
TTGTTTCTGAAACATGGCAAAGGTAGCGTTGCCAATGATGTTACAGATGAGATGGTCAGACTAAACTGGCTGACGGAA
acgGAGTGACTAATTCGTAACCATTGACAGTCTGGTTCAAATGAGTATATATGAAATCTAACTAAATTTTGAAGTAAA
AATTAAATTTTCCTAGATCCACTTCTAGGAAAAACTATTAGAGTACTGGTTTTAGGGAATTGCACTCAAAAGCAAGGT
GACTCGCAGTCTGGGGAATTATTCTACTAGAAGAACTCTAGCAAAACCAGACGCGCATTAGAGAACGAGACTTTTGCT
TTTTTGGCGGAACGTCCCGCCAAAAAGCTTCCAAGAGACTCGATGGTTGAGAAACTTGGCTCCATTGACCGAACCTCC
TCGCGTCAGTGGTTTTGAACAGGAAAGTCAAATCGGAATTGGCCGCGTACTGAAGTTCTGATTGAGGAGATTTAGTTA
ATGGTCACCGACGACGGTCACCACGAAAACGTACAGAAAGGCCCAACCTGAGTTCTGCTATCAATGGCCTATTCCGCG
TCGCCAGCCTGACTTGCCCCCCAAGCACGTATGTCAGGTCGAACCTCGCTTGACGGATGGGCCTTGACTCACAGTCCG
CACCTTACTCTGTTTGCGCCGGTATTGTCGCCTTACTGTGGCCATTTGGCTTTCCGTCCTTGTCCTCTCGCGTGCTCC
CTCGGCGGTCCCCCTTTGCGGACCATAGAAATATCAGGACAGCCCAAAGCGGTGGTGACTAAACTCGCAGTCTAAAGC
ACTACGAACAGTCCCCCCGCCTCGGATACCTTTTTGCCGAAACGGCGCCGGGAGAGTGAAGGGACAATTCATAGAAGG
ACCGTAGAAGGTCCTTTAGAGGCGGGGCAAGCATTCGGTAAAGGCGAGCGGCGTCAGCTTGCTGGCTCGCATCGCTCA
GTCACTCGCTCCTTCGCCTTATATAGGACATAGTGTATAAGACGACTGCGTGGCCACGTCGGAAAAAAGAGGACGGTG
TACTTCGTGAAGTGACTGTGGGAGTAGTCACGGTTGTATCATTCGGTCATATGTGAGGCGATCGCGACTCCAGACGGA
GCACTTCTTCCACAACGACTGAGTATGGTCCGGACTTAGCGGGGTAGTAGGTCGGTCTTTCACTCCCTCGGTGCCAAC
TACTCTCGAAACAACATCCACCTGGTCAACCACTAAAACTTGAAAACGAAACGGTGCCTTGCCAGACGCAACAGCCCT
TCTACGCACTAGACTAGGAAGTTGAGTCGTTTTCAAGCTAAATAAGTTGTTTCGGTGCAACACAGAGTTTTAGAGACT
ACAATGTAACGTGTTCTATTTTTATATAGTAGTACTTGTTATTTTGACAGACGAATGTATTTGTCATTATGTTCCCCA
CAATACTCGGTATAAGTTGCCCTTTGCAGAACGAGCTCCGGCGCTAATTTAAGGTTGTACCTACGACTAAATATACCC
ATATTTACCCGAGCGCTATTACAGCCCGTTAGTCCACGCTGTTAGATAGCTAACATACCCTTCGGGCTACGCGGTCTC
AACAAAGACTTTGTACCGTTTCCATCGCAACGGTTACTACAATGTCTACTCTACCAGTCTGATTTGACCGACTGCCTT
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TTTATGCCTCTTCCGACCATCAAGCATTTTATCCGTACTCCTGATGATGCATGGTTACTCACCACTGCGATCCCCGGG
AAAACAGCATTCCAGGTATTAGAAGAATATCCTGATTCAGGTGAAAATATTGTTGATGCGCTGGCAGTGTTCCTGCGC
CGGTTGCATTCGATTCCTGTTTGTAATTGTCCTTTTAACAGCGATCGCGTATTTCGTCTCGCTCAGGCGCAATCACGA
ATGAATAACGGTTTGGTTGATGCGAGTGATTTTGATGACGAGCGTAATGGCTGGCCTGTTGAACAAGTCTGGAAAGAA
ATGCATAAGCTTTTGCCATTCTCACCGGATTCAGTCGTCACTCATGGTGATTTCTCACTTGATAACCTTATTTTTGAC
GAGGGGAAATTAATAGGTTGTATTGATGTTGGACGAGTCGGAATCGCAGACCGATACCAGGATCTTGCCATCCTATGG
AACTGCCTCGGTGAGTTTTCTCCTTCATTACAGAAACGGCTTTTTCAAAAATATGGTATTGATAATCCTGATATGAAT
AAATTGCAGTTTCATTTGATGCTCGATGAGTTTTTCTAATCAGAATTGGTTAATTGGTTGTAACACTGGCAGAGCATT
ACGCTGACTTGACGGGACGGCGGCTTTGTTGAATAAATCGAACTTTTGCTGAGTTGAAGGATCAGATCACGCATCTTC
CCGACAACGCAGACCGTTCCGTGGCAAAGCAAAAGTTCAAAATCACCAACTGGTCCACCTACAACAAAGCTCTCATCA
ACCGTGGCTCCCTCACTTTCTGGCTGGATGATGGGGCGATTCAGGCCTGGTATGAGTCAGCAACACCTTCTTCACGAG
GCAGACCTCAGCGCTCAAAGATGCAGGGGTAAAAGCTAACCGCATCTTTACCGACAAGGCATCCGGCAGTTCAACAGA
TCGGGAAGGGCTGGATTTGCTGAGGATGAAGGTGGAGGAAGGTGATGTCATTCTGGTGAAGAAGCTCGACCGTCTTGG
CCGCGACACCGCCGACATGATCCAACTGATAAAAGAGTTTGATGCTCAGGGTGTAGCGGTTCGGTTTATTGACGACGG
GATCAGTACCGACGGTGATATGGGGCAAATGGTGGTCACCATCCTGTCGGCTGTGGCACAGGCTGAACGCCGGAGGAT
CgatcCTAGAGCGCACGAATGAGGGCCGACAGGAAGCAAAGCTGAAAGGAATCAAATTTGGCCGCAGGCGTACCGTGG
ACAGGAACGTCGTGCTGACGCTTCATCAGAAGGGCACTGGTGCAACGGAAATTGCTCATCAGCTCAGTATTGCCCGCT
CCACGGTTTATAAAATTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAAT
AAATACGGAGAAGGCTGGTAGTTCGTAAAATAGGCATGAGGACTACTACGTACCAATGAGTGGTGACGCTAGGGGCCC
TTTTGTCGTAAGGTCCATAATCTTCTTATAGGACTAAGTCCACTTTTATAACAACTACGCGACCGTCACAAGGACGCG
GCCAACGTAAGCTAAGGACAAACATTAACAGGAAAATTGTCGCTAGCGCATAAAGCAGAGCGAGTCCGCGTTAGTGCT
TACTTATTGCCAAACCAACTACGCTCACTAAAACTACTGCTCGCATTACCGACCGGACAACTTGTTCAGACCTTTCTT
TACGTATTCGAAAACGGTAAGAGTGGCCTAAGTCAGCAGTGAGTACCACTAAAGAGTGAACTATTGGAATAAAAACTG
CTCCCCTTTAATTATCCAACATAACTACAACCTGCTCAGCCTTAGCGTCTGGCTATGGTCCTAGAACGGTAGGATACC
TTGACGGAGCCACTCAAAAGAGGAAGTAATGTCTTTGCCGAAAAAGTTTTTATACCATAACTATTAGGACTATACTTA
TTTAACGTCAAAGTAAACTACGAGCTACTCAAAAAGATTAGTCTTAACCAATTAACCAACATTGTGACCGTCTCGTAA
TGCGACTGAACTGCCCTGCCGCCGAAACAACTTATTTAGCTTGAAAACGACTCAACTTCCTAGTCTAGTGCGTAGAAG
GGCTGTTGCGTCTGGCAAGGCACCGTTTCGTTTTCAAGTTTTAGTGGTTGACCAGGTGGATGTTGTTTCGAGAGTAGT
TGGCACCGAGGGAGTGAAAGACCGACCTACTACCCCGCTAAGTCCGGACCATACTCAGTCGTTGTGGAAGAAGTGCTC
CGTCTGGAGTCGCGAGTTTCTACGTCCCCATTTTCGATTGGCGTAGAAATGGCTGTTCCGTAGGCCGTCAAGTTGTCT
AGCCCTTCCCGACCTAAACGACTCCTACTTCCACCTCCTTCCACTACAGTAAGACCACTTCTTCGAGCTGGCAGAACC
GGCGCTGTGGCGGCTGTACTAGGTTGACTATTTTCTCAAACTACGAGTCCCACATCGCCAAGCCAAATAACTGCTGCC
CTAGTCATGGCTGCCACTATACCCCGTTTACCACCAGTGGTAGGACAGCCGACACCGTGTCCGACTTGCGGCCTCCTA
GctagGATCTCGCGTGCTTACTCCCGGCTGTCCTTCGTTTCGACTTTCCTTAGTTTAAACCGGCGTCCGCATGGCACC
TGTCCTTGCAGCACGACTGCGAAGTAGTCTTCCCGTGACCACGTTGCCTTTAACGAGTAGTCGAGTCATAACGGGCGA
GGTGCCAAATATTTTAAGAACTTCTGCTTTCCCGGAGCACTATGCGGATAAAAATATCCAATTACAGTACTATTATTA
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GGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTC
AAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCA
ACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAA
AGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGA
GAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGT
CCAAAGAATCTGCAGTCCACCGTGAAAAGCCCCTTTACACGCGCCTTGGGGATAAACAAATAAAAAGATTTATGTAAG
TTTATACATAGGCGAGTACTCTGTTATTGGGACTATTTACGAAGTTATTATAACTTTTTCCTTCTCATACTCATAAGT
TGTAAAGGCACAGCGGGAATAAGGGAAAAAACGCCGTAAAACGGAAGGACAAAAACGAGTGGGTCTTTGCGACCACTT
TCATTTTCTACGACTTCTAGTCAACCCACGTGCTCACCCAATGTAGCTTGACCTAGAGTTGTCGCCATTCTAGGAACT
CTCAAAAGCGGGGCTTCTTGCAAAAGGTTACTACTCGTGAAAATTTCAAGACGATACACCGCGCCATAATAGGGCA
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